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Abstract 
 
Section 1: Chemical-Scale Studies of Ligand-Gated Ion Channels 
 Ligand-gated ion channels are amazing molecular machines that respond to 
specific small-molecule agonists by opening a central pore to enable ions to flow through 
them. In the aggregate, they transduce chemical signals into electrical currents, and they 
have numerous critical physiological functions. The tools of pharmacology and unnatural 
amino acid (and hydroxy acid) mutagenesis enable us to study these receptors on an 
atomic level. Two such projects are presented here. First, the synthesis of a new 5-HT3 
receptor agonist helps to map the receptor’s binding site. Second, mutant cycle analysis 
in the nicotinic acetylcholine receptor with the novel unnatural residue α-hydroxyserine 
(Sah) enables the identification of a crucial hydrogen bond whose formation is part of the 
pathway leading from acetylcholine binding to pore opening. 
 
Section 2: Novel Methods for Phosphonate Synthesis 
 Phosphonates are a key functional group in both organic synthesis and biological 
chemistry. The Arbuzov reaction stands as dominant method available for synthesizing 
this important class of compounds. Two new methods for phosphonate synthesis are 
presented here. The first method enables room-temperature phosphonate synthesis from 
carboxylic acids, taking advantage of a novel Wolff-Kishner-type reductive 
deoxygenation of an intermediate acyl phosphonate. The second method enables 
phosphonate synthesis through the reductive coupling of ketones/aldehydes with dialkyl 
phosphites, mediated by a tosylhydrazone derivative. The latter method requires only 
mild heating (60 °C) and enables access to phosphonates containing azides, benzyl 
halides, and other functional groups poorly tolerated by the Arbuzov conditions. 
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Introduction: Chapter 1 
 
 
 
Introduction: Chemical Synthesis as a Tool for Probing Large, 
Membrane-Bound Proteins 
 
 In the past decades, neuroscience has grown to be one the most active areas of 
research in science today.1 As it has grown, it has become truly interdisciplinary, gaining 
from the contributions of researchers initially trained in biology, physics, and chemistry. 
The action potential—one of the key phenomena of neuroscience—exemplifies this 
multidisciplinary nature: an electric current travels down a cell, and the signal is relayed 
to the next cell by diffusion of a small-molecule neurotransmitter across the synaptic 
cleft.2 The neurotransmitters then bind to transmembrane proteins in the postsynaptic 
neuron that respond by changing conformation to form a pore through which ions can 
enter the postsynaptic neuron to regenerate the action potential (Figure 1.1). 
 These integral membrane proteins are known as ligand-gated ion channels 
(LGICs), and they are one of the two classes of proteins studied in the Dougherty lab. 
The other class is G protein-coupled receptors (GPCRs), many which also bind small-
molecule neurotransmitters. In contrast, GPCRs initiate signaling pathways within the 
cell by activating cytosolic proteins. These two classes of proteins are of great 
physiological and medicinal interest. They are amongst the molecules of learning, 
memory, and sensory perception. They are believed to be the molecular target of many 
drugs of abuse, and their dysfunction has been implicated in a variety of cognitive 
disorders and diseases, including Alzheimer’s, Parkinson’s, schizophrenia, and mood 
  
2 
disorders.3 As such, these receptors are known to be the targets of many commercial 
pharmaceuticals.4 
 In the human nervous system, the Cys-loop superfamily is the most prevalent 
class of LGICs, with its members including the γ-aminobutyric acid type A (GABAA) 
receptor, the serotonin type 3 (5-HT3) receptor, the glycine receptor, and the nicotinic 
acetylcholine (nACh) receptors.5 Of these, the nicotinic acetylcholine receptor (nAChR) 
is the most studied. These receptors are pentameric in structure, with all five subunits 
arranged radially about a central pore (Figure 1.2). Each subunit is similar in structure 
and size, through they are often not all identical. The subunits themselves are quite 
large—roughly 400 amino acid residues and 60 kDa each—and contain large 
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extracellular domains in addition to their four transmembrane helices. Mouse muscle 
nAChR, the family member used in this study, contains four distinct subunits: α (two 
subunits), β, γ, and δ.  The two nonequivalent binding sites are located at the subunit 
interfaces α:γ and α:δ.  Neurotransmitter binding to both sites is typically necessary to 
open the pore, but monoliganded openings are known, particularly for certain mutants.6 
The binding sites are defined by an ‘aromatic binding box;’ these aromatic residues, 
particularly αTrp149, have been shown to bind acetylcholine through the cation-π effect 
(Figure 1.3).7 
 Also of note is βLeu251 (commonly called βLeu9’, where the 9’ designates its 
position on the transmembrane helix #2), which, along with αLeu9’, γLeu9’, and δLeu9’, 
is believed to form the gate of the channel pore. When the leucine side chains are pointed 
into the pore, the channel is closed. Binding of acetylcholine molecules in the two 
extracellular binding sites initiates a conformational change that swings the leucine 
residues to the side, opening the pore and allowing ions to flow through it and across the 
cell membrane (Figure 1.4). It has been demonstrated that mutations at the 9’ sites can 
  
4 
have dramatic effects upon the pore’s propensity to open. In particular, the mutation 
βL9’S is known to alter the pore’s propensity to open by a constant increment over wild-
type. This increment remains constant in the presence of other mutations (it is quantified 
as a 40-fold shift in EC50, see below), which makes it helpful in the study of other 
mutations that would otherwise require a high drug concentration to activate.8 
 GPCRs are structurally quite different from LGICs (Figure 1.5).9 They have seven 
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transmembrane helices, and the agonist binding site is between several of the helices, set 
deep within the transmembrane region, in contrast to the LGIC bindings sites, which are 
in the extracellular portion. Ligand binding activates the G protein, but there are multiple 
intracellular pathways though which the signal might be transduced. There are also a 
wide range of GPCR ligands, including acetylcholine and dopamine. 
 In the Dougherty lab, we typically study these proteins through structure-function 
experiments, and one of the most common tools for assaying function is 
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electrophysiology. There are a variety of 
electrophysiological techniques and 
experiments available, but we use two-
electrode whole-cell voltage clamp for the 
projects described here (Figure 1.6).10 
Starting with a cell that expresses the LGIC 
of interest on its surface, a constant 
potential (voltage clamp) is imposed upon 
the membrane. This is done using two 
electrodes to measure the transmembrane potential and a third electrode to traffic current 
as needed to maintain the specified potential. When the cell is bathed in an agonist, the 
LGICs respond by allowing current to flow across the membrane; the current electrode 
traffics an equal but opposite current to compensate and maintain the specified potential. 
This current can then be correlated to the concentration of agonist applied. When multiple 
concentrations are applied, a dose-current response plot can be constructed to illustrate 
the sensitivity of channel opening to neurotransmitter application (Figure 1.7). The data 
can then be fit to the Hill equation to determine an EC50 value, which represents the 
agonist concentration necessary to produce a half-maximal current response.11 The EC50 
value is thus a powerful metric in assessing receptor function. GPCRs can be assayed in a 
similar way by exploiting a G protein pathway that couples GPCR activation to the 
opening of G protein-coupled inwardly-rectifying potassium channels (GIRKs).12 
 With such a powerful tool for assaying function, the question becomes how to 
probe structure. One strategy is pharmacology: altering the structure of the small-
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molecule agonist, which can be done through synthetic chemistry. This strategy is used 
by many other researchers, though our ability to perform both the chemical synthesis and 
the electrophysiology in-house offers us some advantages. Two pharmacological projects 
are outlined in Chapters 2 and 8. 
 Another common strategy is to vary the structure of the receptor through 
mutagenesis. This typically requires the use of PCR to create genetic material encoding a 
mutant version of the receptor where one or more amino acids have been changed to 
another of the 20 amino acids, thus ablating or altering a peptide sidechain believed to 
have an important functional role. This genetic material must be expressed in a system 
that can be electrophysiologically assayed—in our case, we manually inject mRNA into 
an oocyte of the frog Xenopus laevis, which (usually) will synthesize, fold, and transport 
the protein to the membrane for assaying. 
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 However, conventional mutagenesis is a very common strategy that is 
implemented by many other laboratories. In the Dougherty group, we have developed a 
mutagenesis protocol enabling the incorporation of unnatural amino acids and hydroxy 
acids (Figure 1.8).13 This method greatly expands the structural alterations that can be 
accomplished by mutagenesis, and it enables more specific and targeted questions to be 
asked of the receptors being studied. For example, when studying the role of a tryptophan 
residue, the electronics of the side chain can be altered through the incorporation of ring-
fluorinated analogs without perturbing the side-chain sterics (Figure 1.9). Using 
conventional mutagenesis, the subtlest mutation possible would be to exchange the 
tryptophan for a phenylalanine, which is a pretty significant steric and electronic change. 
This methodology also allows the role of backbone amides to be probed by the 
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incorporation of hydroxy acids, 
something that is not possible using 
conventional mutagenesis (Figure 1.10). 
The incorporation of a hydroxy acid in 
place of an amino acid mutates a 
backbone amide to an ester, eliminating 
one hydrogen bond-donor and weakening 
one hydrogen bond-acceptor in a precisely targeted manner. 
 Unnatural amino acid and hydroxy acid mutagenesis is accomplished by nonsense 
suppression (Figure 1.8).14 In this method mutant mRNA encoding the desired protein is 
made in which the codon of the residue targeted for mutation is mutated to the amber stop 
codon (UAG). In parallel, a chemically synthesized α-amino acid or α-hydroxy acid is 
ligated to an amber-suppressor tRNA (CUA). Those two macromolecules are then 
manually injected into a Xenopus oocyte, which then expresses the mutant receptor of 
interest. 
 Although the many steps of this method have been extensively optimized by the 
Dougherty group and the Schultz group, there is still significant variation from mutant to 
mutant, and a variety of control experiments must always be performed. One concern is 
that the translational machinery of the oocyte is able to bypass the amber stop codon in 
reading the mutant mRNA—either by jumping over that codon or mismatching it with a 
natural tRNA-amino acid couple—a phenomenon known as ‘read-through’. Injection of a 
set of oocytes with mutant mRNA only should give functional receptors only if read-
through is an issue (without read-through or suppressor tRNA, the amber stop codon 
N
OHN
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H
H
Figure 1.10. Incorporation of an α-hydroxy 
acid eliminates a hydrogen bond donor
amino acid
hydroxy acid
N
O
H
N
O
H
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should break off translation before a functional peptide has been made). A second 
problem that can occur is the aminoacylation of the amber suppressor tRNA by a 
naturally occurring aminoacyl tRNA-synthetase after the tRNA’s cargo has been 
incorporated into a polypeptide or hydrolytically lost. This misaminoacylated tRNA can 
then be recycled to incorporate an undesired natural amino acid into the protein. Injection 
of mutant mRNA along with unacylated amber-suppressor tRNA can be done to control 
for this potential problem. Finally, mutant mRNA can be co-injected with amber-
suppressor tRNA that is coupled to the naturally occurring amino acid for the mutated 
site. This control should produce wild-type protein. Projects using this unnatural 
mutagenesis technique are described in Chapters 3, 4, and 7. 
H3N
OH
H3N
OH
H3N
Me
OH
OH
O
OH
O
OH
O
H3N
OPO32-
H3N
OPO32-
H3N
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OPO32-
OH
O
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O
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O
H2N
CH2PO32-
H2N
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CH2PO32-
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O
OH
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Threonine
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pTyrosine
pThreonine
pSerine
p*Tyrosine
p*Threonine
p*Serine
Figure 1.11. Serine, threonine, and tyrosine, their phosphorylated 
derivatives, and the phosphonate-based analogs that serve as
nonhydrolyzable phophate ester mimics
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 One interesting biochemical phenomenon that can theoretically be studied using 
this unnatural mutagenesis technique is protein phosphorylation (Figure 1.11). In 
phosphorylation, serine, threonine, and tyrosine residues enzymatically have a phosphate 
group appended to them, altering the behavior, structure, and/or function of the protein. 
This posttranslational modification is a key regulatory mechanism governing most 
proteins, and LGICs and GPCRs are no exceptions. The Dougherty lab has previously 
reported on the incorporation of photocaged tyrosine, as well as photocaged 
phosphoserine, phosphothreonine, and phosphotyrosine as tools for studying the effects 
of phosphorylation of specific sites.15 Unfortunately, this strategy is not very useful when 
the proteins are expressed in live cells because native phosphatases are capable of 
cleaving the phosphate esters of the mutant proteins.16 In this case, caged phosphonates 
may be useful as nonhydrolyzable phosphate ester mimics.17 In pursuing the syntheses of 
phosphonoserine, phosphonothreonine, and phosphonotyrosine derivatives, new methods 
for phosphonate synthesis were explored and developed, and these are presented in 
Chapters 5 and 6. 
 In Chapter 7, a less common type of 
protein posttranslational modification was 
considered: cysteine nitrosylation (Figure 
1.12).18 The modification is much more poorly 
understood than phosphorylation, though it has 
been identified as physiologically relevant for hemoglobin and several glutamate 
receptors. Even relatively basic questions about the timescale of the modification are 
H3N
SH
OH
O
H3N
S
OH
O
Cysteine Nitrosocysteine
N
O
Figure 1.12. Cysteine nitrosylation is a 
postranslational modification.
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unanswered, and we try to understand it through the use of unnatural amino acids and a 
small molecule model system. 
  
13 
References 
                                                
1 (a) Neuroscience. Purves, D., et. al. Sinauer Associates. 2001. (b) Nicotinic 
acetylcholine receptors of muscles and nerves—Comparison of their structures, 
functional roles, and vulnerability to pathology in Myasthenia Gravis and Related 
Disorders. Lindstrom, J. 2003. (c) Physical Organic Chemistry on the Brain. Dougherty 
DA. J. Org. Chem. 2008, 73, 3667–3673. 
2 (a) Membrane action potentials from the squid giant axon. Curtis, HJ, and Cole, KS. 
Journal of Cellular and Comparative Physiology. 15, 1940, 147-157. (b) Membrane 
potential of the squid giant axon during current flow. Cole, KS, and Curtis, HJ. Journal of 
General Physiology. 24, 1941, 551-563. (c) Membrane resting and action potentials from 
the squid giant axon. Curtis, HJ, and Cole, KS. Journal of Cellular and Comparative 
Physiology. 19, 1942, 135-144. 
3 (a) Corringer, P. J., Le Novere, N., and Changeux, J. P. Annu. Rev. Pharmacol. Toxicol., 
2000, 40, 431–458. (b) Grutter, T., and Changeux, J. P., 2001, Trends Biochem. Sci. 26, 
459–463. (c) Karlin, A. Nat. Rev. Neurosci., 2002, 3, 102–114. 
4 (a) The druggable genome. Hopkins AL, Groom CR. Nat. Rev. Drug Discov., 2002, 1, 
727–730. (b) Drug design strategies for targeting G-protein-coupled receptors. Klabunde, 
T., Hessler, G. Chembiochem., 2002, 3, 928–944. 
5 (a) Sequence and Functional Expression of the Gaba-a Receptor Shows a Ligand-Gated 
Receptor Super-Family. Schofield, P.R., Darlison, M.G., Fujita, N., Burt, D.R., 
Stephenson, F.A., Rodriguez, H., Rhee, L.M., Ramachandran, J., Reale, V., Glencorse, 
T.A., Seeburg, P.H. and Barnard, E.A. Nature. 328, 1987, 221-227. (b) Emerging 
structure of the nicotinic acetylcholine receptors. Karlin, A. Nature Reviews 
Neuroscience. 3, 2002, 102-114. (c) Refined structure of the nicotinic acetylcholine 
receptor at 4 angstrom resolution. Unwin, N. Journal of Molecular Biology. 346, 2005, 
967-989. 
6 (a) Short openings in high resolution single channel recordings of mouse nicotinic 
receptors. Hallermann, S., Heckmann, S., Dudel, J., and Heckmann, M. Journal of 
Physiology-London. 563, 2005, 645-662. (b) A human congenital myasthenia-causing 
mutation (epsilon L78P) of the muscle nicotinic acetylcholine receptor with unusual 
  
14 
                                                
single channel properties. Shelley, C., and Colquhoun, D. Journal of Physiology—
London. 564, 2005, 377-396. 
7 From ab initio quantum mechanics to molecular neurobiology: A cation-pi binding site 
in the nicotinic receptor. Zhong, W.G., Gallivan, J.P., Zhang, Y.O., Li, L.T., Lester, H.A. 
and Dougherty, D.A. PNAS. 95, 1998, 12088-12093. 
8 Agonist binding site of the nicotinic acetylcholine receptor: Tests with novel side chains 
and with several agonists. Kearney, P.C., Nowak, M.W., Zhong, W., Silverman, S.K., 
Lester, H.A. and Dougherty, D.A. Molecular Pharmacology. 50, 1996, 1401-1412. 
9 (a) Structural diversity of G protein-coupled receptors and significance for drug 
discovery. Lagerstrom MC, Schioth HB. Nat. Rev. Drug Discov., 2008, 7, 339–357; 
erratum 542. (b) GPCR engineering yields high-resolution structural insights into 2-
adrenergic receptor function. Rosenbaum DM, et al. Science., 2007, 318, 1266–1273. (c) 
Crystal structure of the human beta2 adrenergic G protein-coupled receptor. Rasmussen 
SGF, et al. Nature., 2007, 450, 383–387. (d) Crystal structure of rhodopsin: A Gprotein-
coupled receptor. Palczewski K, et al. Science., 2000, 289, 739–745. 
10 The Axon Guide. Sherman-Gold, R., et. al. Axon Instruments, 1993. 
11 (a) The combinations of haemoglobin with oxygen and with carbon monoxide. I. Hill, 
A.V. Biochemical Journal. 7, 1913, 471-480. (b) The Hill equation revisited: uses and 
misuses. Weiss, J.N. Faseb Journal. 11, 1997, 835-841. 
12 Probing the Role of the Cation-π Interaction in the Binding Sites of GPCRs Using 
Unnatural Amino Acids, M. M. Torrice, K. S. Bower, H. A. Lester, D. A. Dougherty, 
Proc. Natl. Acad. Sci., 2009, 106, 11919-11924 and references therein. 
13 (a) Nicotinic Receptor Binding Site Probed with Unnatural Amino-Acid Incorporation 
in Intact Cells. M. W. Nowak, P. C. Kearney, J. R. Sampson, M. E. Saks, C. G. Labarca, 
S. K. Silverman, W. Zhong, J. Thorson, J. N. Abelson, N. Davidson, P. G. Schultz, D. A. 
Dougherty, and H. A. Lester, Science, 1995, 268, 439-442. (b) In Vivo Incorporation of 
Unnatural Amino Acids into Ion Channels in a Xenopus Oocyte Expression System. M. 
W. Nowak, J. P. Gallivan, S. K. Silverman, C. G. Labarca, D. A. Dougherty, and H. A. 
Lester, in Methods in Enzymology, 1998, 293, Ion Channels, Part B, E. P. Conn, Ed., 
Academic Press: San Diego, pp. 504-529. (c) Incorporation of Esters into Proteins: 
  
15 
                                                
Improved Synthesis of Hydroxyacyl tRNAs. P. M. England, H. A. Lester, D. A. 
Dougherty, Tetrahedron Lett. 1999, 40, 6189-6192. 
14 see reference 13 
15 (a) Flash Decaging of Tyrosine Sidechains in an Ion Channel. J. C. Miller, S. K. 
Silverman, P. M. England, D. A. Dougherty, and H. A. Lester, Neuron, 1998, 20, 619-
624. (b) Tyrosine Decaging Leads to Substantial Membrane Trafficking during 
Modulation of an Inward Rectifier Potassium Channel. Y. Tong, G. S. Brandt, M. Li, G. 
Shapovalov, E. Slimko, A. Karschin, D. A. Dougherty, and H. A. Lester, J. Gen. Phys. 
2001, 117, 103-118. (c) Caged Phosphoproteins Deborah M. Rothman, E. James 
Petersson, M. Eugenio Vázquez, Gabriel S. Brandt, Dennis A. Dougherty, Barbara 
Imperiali J. Am. Chem. Soc., 2005, 127, 846-847. 
16 (a) Protein phosphatase activities in vivo in Xenopus laevis oocyte: Inhibition by 
okadaic acid Cormier, P.; Mulner-Lorillon, O.; Ozon, R.; Bellé, R. Biology of the Cell. 
1990, 69, 233-236. (b) Cardiac calcium channels expressed in Xenopus oocytes are 
modulated by dephosphorylation but not by cAMP-dependent phosphorylation. Singer-
Lahat D, Lotan I, Biel M, Flockerzi V, Hofmann F, Dascal N. Receptors Channels. 1994, 
2(3), 215-26. 
17 (a) Brandt, G. S. Ph.D. Dissertation, California Institute of Technology, Pasadena, CA, 
2003. (b) Chen, L.; Wu, L.; Otaka, A.; Smyth, M. S.; Roller, P. P.; Burke, T. R.; 
Denhertog, J.; Zhang, Z. Y. Biochem. Biophys. Res. Commun. 1995, 216, 976. (c) Engel, 
R. Chem. Rev. 1977, 77, 349. (d) Nieschalk, J.; Ohagan, D. J. Chem. Soc., Chem. 
Commun. 1995, 719. (e) Oleksyszyn, J.; Powers, J. C. In Proteolytic Enzymes: Serine and 
Cysteine Peptidases; Academic Press Inc: San Diego, 1994; 244, 423. (f) Panigrahi, K.; 
Eggen, M.; Maeng, J. H.; Shen, Q. R.; Berkowitz, D. B. Chem. Biol. 2009, 16, 928 (g) 
Petersson, E. J. Ph.D Dissertation, California Institute of Technology, Pasadena, CA, 
2005. (h) Zheng, W. P.; Schwarzer, D.; LeBeau, A.; Weller, J. L.; Klein, D. C.; Cole, P. 
A. J. Biol. Chem. 2005, 280, 10462. (i) Zheng, W. P.; Zhang, Z. S.; Ganguly, S.; Weller, 
J. L.; Klein, D. C.; Cole, P. A. Nat. Struct. Biol. 2003, 10, 1054. 
18 (a) Protein S-nitrosylation: Purview and Parameters. Hess, D. T.; Matsumoto, A.; Kim, 
S.-O.; Marshall, H. E.; Stamler, J. S. Nature Reviews. 2005, 6, 150-166. (b) Crystal 
  
16 
                                                
Structure of the S-Nitroso Form of Liganded Human Hemoglobin. Chan, N.-L.; Rogers, 
P. H.; Arnone, A. Biochemistry. 1998, 37, 16459-16464. 
  
17 
Section 1: Chapter 2 
 
 
 
The Synthesis of 1-oxo-5-hydroxytryptamine to Probe Ligand-Receptor 
Interactions in the 5-HT3 Receptor1 
 
 
Abstract: A novel synthetic route to 1-oxo-5-hydroxytryptamine, the benzofuran 
analog of serotonin, has been developed. The new synthesis proceeds via the [3+2] 
cycloaddition of p-benzoquinone and 2,3-dihydrofuran, followed by a Lewis acid-
catalyzed isomerization. This molecule proves to be a competent agonist (equipotent to 
serotonin) of the 5-HT3 receptor, demonstrating that the indolic proton of serotonin is not 
essential to its activation of the receptor.  
 
 As part of the Dougherty group’s efforts towards better understanding the Cys-
loop ligand-gated ion channels, Kiowa Bower in the lab has been mapping out the 
binding site of the 5-HT3 receptor, a homopentameric member of the superfamily that 
responds to 5-hydroxytryptamine (a.k.a. serotonin, 1).2,3 In the course of this work, he 
identified a tyrosine residue that might accept a hydrogen bond from the indole nitrogen 
of 5-HT, but the data were ambiguous. We therefore proposed that an analog of the 
native agonist—one in which the indole nitrogen is replaced by an oxygen—would 
elucidate this question. This proposed molecule is 3-(2-aminoethyl)benzofuran-5-ol, 
which we refer to as 1-OT (1-oxo-5-hydroxytryptamine, 2), for consistency with 5-HT 
and related compounds (Figure 2.1).  
 1-OT has been 
synthesized once before,4 but it 
has never been explicitly tested 
on the 5-HT3 receptor. In fact, 
N
H
HO
NH3
O
HO
NH3
21
Figure 2.1. 5-hydroxytryptamine (1) and its analog 
1-oxo-5-hydroxytryptamine (2)
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the only prior study on this molecule was one in which the rate of muscular contraction of 
surgically removed rat fundus strips was measured following drug application.5 The 
published synthesis (10 steps and < 3% yield) was cumbersome, prompting the pursuit of 
a novel synthetic strategy that could provide more ready access to 2. Identification of the 
quinone synthon within the target molecule suggested a synthetic route utilizing a [3+2] 
cycloaddition between p-benzoquinone and an electron-rich olefin, yielding the 
benzofuran core in a single step (Scheme 2.1). 
 Initial attempts focused on the cycloaddition of 5 with enamine 6, which, when 
subjected to acidic workup conditions, was expected to give ring-opened product, 1-OT 
2. However, consistent with previous reports, pyrroline (6) proved very difficult to work 
with due to its high reactivity (pyrroline reacts with itself to form a readily oxidizable 
trimer, which must be broken up by heat immediately prior to reaction).6 No desired 
products could be isolated from the reaction mixture, which formed a black tar, even at 
cryogenic temperatures. Protection of pyrroline with a carbamate or amide was then 
considered to reduce its nucleophilic reactivity. However, the N-benzoyl pyrroline (7) 
failed to react with p-benzoquinone, even at elevated temperatures. 
 A strategy involving the installation of the primary amine subsequent to formation 
of the heterocyclic framework was then considered (Scheme 2.2). The tricycle 4 is a 
known compound that can be synthesized enantioselectively from 5 and 2,3-dihydrofuran 
O
HO
NH3
2
O
HO
X O
O
X
5 6: X = NH
7:    = NBz
8:    = O
3: X = NH
4:    = O
Scheme 2.1. 1-OT retrosynthesis
  
19 
(8) using a Lewis acid catalyst developed by Corey.7 Circumventing the multistep 
synthesis of the Corey catalyst, we discovered that the same transformation can be 
accomplished racemically by BF3•Et2O, albeit in much poorer yield. The reaction was 
messy, even at -100 °C, but poor (10-20%) yields of the desired tricycle 4 could be 
isolated. A screen of other Lewis acids failed to produce markedly better results. 
 The postulated ring-opening reaction was then explored. Refluxing HCl or HBr 
failed to yield the desired alcohol 9 or the corresponding alkyl halide. However, 
treatment of 4 with BF3•Et2O at slightly elevated temperatures produced 9 in good yield. 
The similarity of these conditions to those of the cycloaddition step, suggested that a one-
pot cascade synthesis of 9 from benzoquinone and 2,3-dihydrofuran might be possible.  
This route was investigated but was not realized. 9 could not be isolated from the reaction 
of 5 with 8, even when subjected to longer reaction times, elevated catalyst loadings, 
and/or elevated temperatures. Using the crude cyclization product 4 in the ring-opening 
reaction led to no alcohol 9, but did result in the consumption of 4. Starting materials or 
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Scheme 2.2. Synthesis of 1-OT
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side products from the cycloaddition step may interfere with the ring opening (for 
example, p-benzoquinone may be capable of oxidation of tricycle 4 or alcohol 9 at faster 
rates than ring-opening).8 In the previously reported synthesis of tricycle 4, p-
benzoquinone gave significantly poorer yields than more electron rich benzoquinones. A 
screen of other Lewis acids (e.g., AlCl3, InCl3, MgBr2, etc.) in the desired cascade 
synthesis also failed. These observations suggest that—if a catalyst exists for this 
sequence—it is likely to be sterically bulky and quite Lewis acidic, as is the case with the 
Corey catalyst. 
 Primary alcohol 9 was then converted to protected amine 11 using Fukuyama’s 
modified Mitsunobu protocol in quantitative yield.9  Removal of the nosyl group 
according to Fukuyama likewise proceeded in quantitative yield, giving Boc-protected 1-
OT 11b. After some experimentation with the reaction conditions, it was discovered that 
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the crystalline hydrochloride salt of 1-OT (2) could be isolated in high purity and good 
yield via deprotection of 11b using HCl in chloroform/methanol, followed by 
crystallization from anhydrous ether. 
 The pharmacology of 2 on the 5-HT3 receptor proved very interesting, with an 
EC50 value nearly identical to that of the native agonist (1.7±0.06 vs. 1.2±0.03 µM, 
respectively; Figure 2.2). Furthermore, 2 is essentially a full agonist, with an efficacy that 
is 94±4% of 1. These data strongly indicate that the indole NH of 1 is not important for 
receptor activation. Comparison of 1-OT to 5-fluorotryptamine (5-FT, 12, EC50 = 18 
µM)—an agonist that likewise differs from serotonin by the elimination of one hydrogen 
bond donor—emphasizes how well 1-OT mimics serotonin in the 5-HT3 receptor. 
 In conclusion, an efficient new route to 1-oxo-5-hydroxytryptamine, the 
benzofuran analog of serotonin, has been established. This molecule is a competent 
agonist of the 5-HT3 receptor, suggesting that the indole nitrogen of 1 does not donate a 
hydrogen bond to the receptor. The increased availability of 2 afforded by the synthetic 
route described here will enable similar studies to elucidate agonist binding in the other 
six classes of 5-HT receptors, perhaps providing a class-specific agonist. In addition, this 
route should be easily modifiable (through the use of substituted benzoquinones and 
dihydrofurans) to synthesize more substituted 1-OT derivatives for further elucidation of 
5-HT receptor binding sites. 
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Chemistry—General 
 
All reactions were performed under argon using solvents that were dried and purified 
according to the method of Grubbs.10 All flasks and vials were oven dried at 122 °C and 
cooled in a desiccator box containing anhydrous calcium sulfate. Commercial reagents 
were purified according to the methods compiled by Armengo and Perrin.11 Hydrogen 
chloride gas was generated in situ by dropwise addition of concentrated HCl into stirred 
concentrated H2SO4.  Reactions were monitored by thin-layer chromatography on Merck 
Siligel 60-F254. Compounds were visualized with UV lamp (254 nm) and stained with 
ceric ammonium molybdate solution.  Column chromatography was carried out in 
accordance with the methods of Still12 using EMD-Merck silica gel 60, 230-400 mesh 
ASTM or Aldrich Brockmann I alumina, 150 mesh (for acid-sensitive compounds such 
as pyrroline). 1H and 13C NMR spectra were acquired on a Varian Mercury 300 MHz 
spectrometer. High-resolution mass spectrometry was performed on a JEOL JMS-600H 
HRMS using an Electrospray Ion Source. Copies of NMR spectra of the synthesized 
compounds can be found in the supporting information section of our submission of this 
work to Organic Letters.1 
 
 
Chemistry—Synthesis 
 
(4). Boron trifluoride-diethyl etherate (0.6 mL, 5 mmol) was added to a mixture of 
acetonitrile (10 mL) and dichloromethane (30 mL) in a 100 mL round-bottomed flask and 
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cooled to -78 °C.  A solution of p-benzoquinone (540 mg, 5 mmol) and 2,3-dihydrofuran 
(2,3-DHF, 0.6 mL, 7.5 mmol) in acetonitrile (10 ml) was then added to the stirred BF3 
solution at -78 °C by syringe pump over 2 h.  After 5 total hours, additional 2,3-DHF (0.6 
mL, 7.5 mmol) was added dropwise over 10 minutes.  After 8 total hours, the reaction 
temperature was allowed to slowly rise to room temperature over the following hour, at 
which point methanol (10 mL) and 1 N HCl (10 mL) were added. The product was 
extracted with 4 x 30 mL dichloromethane, washed with 1 x 30 mL brine, dried on 
magnesium sulfate, and reduced in vacuo. The residue was then filtered through a silica 
plug with ethyl acetate, then purified by flash chromatography on silica (25% EtOAc in 
hexanes). The product fraction could be purified further by recrystallization from 3 mL 
toluene to yield flaky, white crystals; 160 mg (18%) 4. 1H NMR (300 MHz, CDCl3) δ 
6.59-6.70 (m, 3H), 6.27 (d, 1H, J = 6 Hz), 4.66 (s, 1H, OH), 4.05 (t, 1H, J = 8 Hz), 3.95 
(t, 1H, J = 7 Hz), 3.58-3.64 (m, 1H), 2.22-2.29 (m, 1H), 2.03 (dd, 1H, J = 12, 4.5 Hz); 13C 
NMR (75 MHz, CDCl3) δ 153.6, 150.5, 128.9, 115.5, 112.1, 111.3, 109.6, 67.5, 47.2, 
33.6; HRMS (EI+) calculated for [C10H10O3] ([M]+) 178.0630, found 178.0638.  The 
characterization data matched reported values for this compound synthesized using the 
Corey oxazaborolidine catalyst.7 
 
(9). 4 (89 mg, 0.50 mmol) was measured into a 2 dram vial, and acetonitrile (5 mL) was 
added to dissolve it.  Boron trifluoride-diethyl etherate (140 uL, 1.1 mmol) was then 
added.  The vial was then shaken at 37 °C for 22 h.  Aqueous HCl (4 mL, 1 N) was then 
added, and the product was extracted with 5 x 8 mL dichloromethane, dried on sodium 
sulfate, and reduced in vacuo.  The residue was then purified by flash chromatography on 
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silica (50% EtOAc in hexanes) to yield 74.1 mg (83%) 9. 1H NMR (300 MHz, acetone-
d6) δ 8.03 (s, 1H), 7.58 (s, 1H), 7.27 (d, 1H, J = 9 Hz), 7.01 (d, 1H, J = 3 Hz), 6.81 (dd, 
1H, J = 9, 3 Hz), 3.99 (s, 1H), 3.82 (t, 2H, J = 6 Hz), 2.82 (t, 2H, J = 6 Hz); 13C NMR (75 
MHz, acetone-d6) δ 153.9, 150.0, 143.8, 129.8, 118.0, 113.5, 112.0, 104.9, 61.6, 27.5; 
HRMS (EI+) calculated for [C10H10O3] ([M]+) 178.0630, found 178.0628. 
 
(11). 9 (193 mg, 1.1 mmol), triphenylphosphine (341 mg, 1.3 mmol), and N-Boc-o-
nitrobenzenesulfonamide (393 mg, 1.3 mmol) were measured into a 2 dram vial.  THF (5 
mL) was added.  Diisopropyl azodicarboxylate (256 uL, 1.3 mmol) was added to the 
stirred solution by a syringe over a 10 minute period.  After an additional 20 minutes 
stirring at room temperature, the reaction was reduced in vacuo, and the residue was 
triturated with toluene (5 mL) to give 372.7 mg of a white solid.  Additional product 
could be recovered by flash chromatography of the filtrate on silica (30% EtOAc in 
hexanes), followed by trituration of the product fraction to give a total yield of 483.0 mg 
(96 %) 11. 1H NMR. (300 MHz, acetone-d6) δ 8.28-8.31 (m, 1H), 7.95-8.02 (m, 3H), 7.70 
(s, 1H), 7.32 (d, 1H, J = 9 Hz), 7.14 (d, 1H, J = 2 Hz), 6.86 (dd, 1H, J = 9, 2 Hz), 4.03 (t, 
2H, 7 Hz), 3.08 (t, 2H, 7 Hz), 1.27 (s, 9H); 13C NMR (75 MHz, acetone-d6) δ 153.7, 
150.4, 150.0, 143.6, 135.3, 133.0, 132.6, 132.5, 128.9, 124.9, 116.6, 113.4, 111.7, 104.5, 
85.0, 47.2, 27.1, 21.6; HRMS (EI+) calculated for [C21H22N2O8S] ([M]+) 462.1097, found 
462.1100. 
 
1-oxa-5-hydroxytryptamine hydrochloride (2).  11 (445 mg, 0.96 mmol) was measured 
into a 25 mL round-bottomed flask.  DMF (9.6 mL), followed by lithium hydroxide 
  
25 
monohydrate (162 mg, 3.85 mmol) and mercaptoacetic acid (134 uL, 1.93 mmol), were 
then added.  After 6 h room temperature stirring, the reaction was poured onto 60 mL 
aqueous sodium bicarbonate, and the product was extracted with 5 x 20 mL EtOAc, 
washed with 1 x 20 mL brine, reduced in vacuo, and filtered through a silica plug (30% 
EtOAc in hexanes) to yield 247 mg, which was transferred into a 50 mL 3-neck flask 
appended with an HCl purge.  Chloroform (20 mL) and methanol (2 mL) were added, 
and HCl was purged through the stirring solution for 30 minutes.  The reaction was then 
reduced in vacuo, and the residue was redissolved in acetone (5 mL).  This acetone 
solution was then added dropwise to a stirring beaker of ether (20 mL); the resultant 
white crystals were then isolated by filtration to yield 130 mg (64%, 2 steps) 1-oxa-5-
hydroxytryptamine hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ 9.31 (s, 1H, OH), 
8.13 (s, 3H, NH), 7.78 (s, 1H), 7.34 (d, 1H, J = 8 Hz), 6.95 (d, 1H, J = 2 Hz), 6.78 (dd, 
1H, J = 9, 2 Hz), 3.06 (t, 2H, J = 8 Hz), 2.91 (t, 2H, J = 8 Hz); 13C NMR (75 MHz, 
DMSO-d6) δ 154.0, 149.4, 144.1, 128.7, 116.1, 113.9, 112.3, 104.7, 38.7, 22.0; HRMS 
(EI+) calculated for [C10H11NO2] ([M]+) 177.0790, found 177.0794. 
 
 
Molecular Biology and Electrophysiology 
 
The measurement of EC50 and efficacy values for 5-HT, 1-OT, and 5-FT was carried out 
by Kiowa Bower using methods described previously.13 Briefly, the 5-HT3 receptor was 
expressed in Xenopus laevis oocytes by manual injection of the corresponding mRNA. 
Following 1-3 days incubation at 18 °C, transmembrane current in response to drug 
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application was measured using a two-electrode whole-cell voltage clamp. From these 
data a dose-response curve was created for each drug and was fit to the Hill equation. 
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Section 1: Chapter 3 
 
 
 
The Synthesis of α-Hydroxy Acids to Probe Hydrogen Bonding1 
 
 
Abstract: To study the role of specific hydrogen bonds involving the polypeptide 
backbone of the nicotinic acetylcholine receptor, the α-hydroxy acid derivatives of serine 
(Sah) and of asparagine (Nah) were prepared. The asparagine derivative offered a 
significant challenge in its propensity to cyclize into a succinimde, which could be 
overcome by the covalent attachment of a steric blocking group to the amide. 
 
 Elimination of a main-chain amide proton from a large integral membrane protein 
without perturbing the structure in other ways is no simple task. In the Dougherty lab, we 
use α-hydroxy acid mutagenesis by nonsense suppression to accomplish this, a strategy 
that requires the chemical synthesis of the ester of the desired α-hydroxy acid and the 
dinucleotide dCA.2 Incorporation of this α-hydroxy acid yields a protein with a single, 
specific hydrogen bond donor eliminated, though there is a secondary effect of 
decreasing the hydrogen bond-accepting ability of the adjacent carbonyl (Figure 3.1).3 
 For this study, the backbone 
hydrogen bond donors of interest were 
adjacent to asparagine and serine 
residues, requiring the synthesis of α-
hydroxy asparagine-dCA (Nah-dCA; 1) 
and α-hydroxy serine-dCA (Sah-dCA; 2; 
Figure 3.2). The synthesis of Nah-dCA 
proved to be a challenging task. A search of the literature indicated that it had not been 
made before; however, an early Schultz paper showed that they had attempted to make at 
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Figure 3.1. Incorporation of an α-hydroxy 
acid eliminates a hydrogen bond donor
amino acid
hydroxy acid
N
O
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H
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least one Asn-dCA analog, but could never get the 
final step (dCA ester formation) to work and 
ultimately gave up.4 Similarly, at least three 
members of the Dougherty group have attempted to 
synthesize Asn-dCA analogues, also with no success. It has been posited that cyclization 
of the terminal amide into the acid/ester group to form a succinimide was the source of 
the difficulty, but this had not been demonstrated, in part because the isolation of these 
highly polar molecules is itself a challenge. 
 The synthetic route 
first attempted followed 
standard protocols for the 
preparation of α-hydroxy-dCA 
esters (Scheme 3.1).5 α-
Hydroxy asparagine (3) was prepared from asparagine using aqueous sodium nitrite.6 
Cyanomethyl esterification of 3 using triethylamine only gave trace product. A screen of 
different bases revealed that dry Potassium carbonate was able to give 4 in poor (10-20%) 
yields. Attempts at coupling 4 to dCA using the well-established procedure of combining 
the cyanomethyl ester with basic dCA•2.4 TBA in DMF at room temperature gave a 
disheartening result: even if the reaction had worked (which seemed unlikely), the 
reactants could not be separated by HPLC. 
 Therefore a second route, in which a ‘greasy’ protecting group was attached to 3 
to improve HPLC separation, was attempted (Scheme 3.2). This strategy had been 
successfully employed once before in the synthesis of α-hydroxy alanine-dCA (Aah-
HO OdCA
O
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HO OdCA
O
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O 1 2
Figure 3.2. Nah-dCA (1) and Sah-
dCA (2).
HO OH
O
NH2
O
HO O
O
NH2
O
HO OdCA
O
NH2
O
K2CO3
CNCH2Cl
CN
143
Scheme 3.1. Nah-dCA synthesis, route #1 (failed).
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dCA).7 First, Nah-methyl ester 5 was made by Fischer esterification, followed by TBS 
protection of the α-hydroxy group. At this point, only a series of transesterifications and 
a deprotection were necessary to access 1, but the first step—cleavage of the methyl 
ester—proved very difficult. Only succinimide 7 was isolated under a number of reaction 
conditions. Interestingly, when 7 was allowed to stand for several days in aqueous base, 
the desired free acid 9 could be isolated, along with isomer 8. In this basic  hydrolysis 
reaction, there are two imide carbonyls susceptible hydroxide attack; they are 
desymmetrized by the OTBS group, which should activate the closer carbonyl 
electronically but deactivate it sterically.  The experiment suggests that the electronic 
effect dominates the steric effect in this case, as the desired α-silyloxy acid 9 is formed 
preferentially over the isomeric β-silyloxy acid 8 by a ratio of 5:1. Direct lyophilization 
of the crude reaction mixture gave the carboxylate salt 9, which could be directly 
converted to the cyanomethyl ester 10 by direct addition of chloroacetonitrile. 
Unfortunately, 10 could not be coupled to dCA.  After several hours of reaction, no dCA 
ester could be identified by HPLC or TLC, and all cyanomethyl ester 10 had cyclized to 
7. 
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Scheme 3.2. Nah-dCA synthesis, route #2 (failed).
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 The substrate needed to be modified to prevent imide formation. Two distinct 
strategies were envisioned: the amide could be tethered to make the ester physically 
inaccessible; or the nucleophilicity of the amide could be reduced through the addition of 
steric bulk. We chose the latter strategy, reasoning that this solution might be more  
broadly applicable to other asparagine derivatives. Nearly a dozen protecting groups were 
screened for this role (Table 3.1). The TIPS group showed the most promise in this 
screen. Incorporating this protecting group into the synthesis, primary amide 6 was 
TBSO OMe
O
NH2
O
TBSO OMe
O
NHTIPS
O
TBSO O
O
NHTIPS
O
TBSO O
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Scheme 3.3. Nah-dCA synthesis, route #3.
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treated with TIPS triflate and base to give 11 (Scheme 3.3). Deprotection of this ester was 
accomplished with KOTMS in ether to give the salt 12, which was immediately 
suspended in chloroacetonitrile to give the cyanomethyl ester 13. To our relief, this 
compound successfully coupled to dCA, albeit in very low yields. This dCA ester was 
then successfully deprotected in a 1 : 1 : 3 mixture of water : THF : acetic acid to give 
Nah-dCA 1. 
 
 The synthesis of Asn-dCA 15 required more than a simple extension of the Nah-
dCA synthesis (Scheme 3.4). Given that literature precedent suggested that a 
cyanomethyl ester should be stable enough to survive all the steps of the Nah-dCA 
synthesis, we hoped to bypass the need for a methyl ester.8 Beginning with asparagine, 
treatment with nitroveratryl chloroformate in aqueous sodium carbonate yielded NVOC-
Asn 17. This compound was converted directly to cyanomethyl ester 18 by treatment 
with chloroacetonitrile and slow titration with triethylamine. Primary amide 18 could 
then be protected with TIPS triflate to give the coupling precursor 19. Unfortunately, all 
that could be isolated from the dCA coupling reaction was succinimide and silylated 
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O
NH2
O
NVOCHN OH
O
NH2
O
NVOCHN O
O
NH2
O
NVOCHN O
O
NHTIPS
O
NVOCHN OdCA
O
NHTIPS
O
CN
NVOCCl
Na2CO3
16 1817
19 20
NVOCHN OdCA
O
NH2
O
15
CHCH2Cl 
TEA
TIPSOTf 
lutidine
CN
Scheme 3.4. Asn-dCA synthesis (failed).
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dCA. These results suggest that the α-silyloxy cyanomethyl ester is more reactive than 
the α-N-carbamoyl cyanomethyl ester towards the dCA nucleophile. Clear precedent to 
support or challenge this observation is lacking: the Hammett parameters of methoxy and 
acetamido are roughly the same, but methoxy and acetamido are imperfect models for the 
electronics of OTBS and NHNVOC, respectively, and the Hammett parameters do not 
account for steric effects.9 Neither dCA-coupling reaction is homogeneous, so there may 
be solubility effects as well. 
 
 The synthesis of Sah-dCA (2) proceeded more smoothly (Scheme 3.5). Similar to 
the cyanomethyl esters of Nah and Aah, the cyanomethyl ester of Sah could not be 
separated from dCA by HPLC.  It was therefore necessary to protect at least one of the 
hydroxyl groups. Starting with the calcium salt of glycerate (21), Fischer esterification 
yielded methyl ester 22. TBS protection of both hydroxyl groups to give 23 was followed 
by KOTMS deprotection of the methyl ester to give carboxylate salt 24. Addition of 
chloroacetonitrile to the salt yielded coupling precursor 25. The coupling reaction of 25 
and dCA proceeded smoothly to give protected product 26. Deprotection in 1 : 1 : 3 of 
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Scheme 3.5. Sah-dCA synthesis.
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water : THF : acetic acid yielded Sah-dCA 2. 
 These syntheses demonstrate a strategy that may be more broadly applicable in 
the syntheses of other amino acid-dCA and α-hydroxy acid-dCA esters. Specifically, the 
one-pot conversion of methyl esters to cyanomethyl esters using the KOTMS-
chloroacetonitrile sequence is demonstrated here for the first time. Often in other 
syntheses, there is a need to protect the ester with a group that is stable to acid and mild 
base. This method allows easy conversion of a methyl ester—which has those 
properties—to a cyanomethyl ester, which is the precursor activated ester needed for the 
dCA coupling/transesterification reaction. 
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Chemistry—General 
 
All reactions were performed under argon using solvents that were dried and purified 
according to the method of Grubbs.10 All flasks and vials were oven dried at 122 °C and 
cooled in a desiccator box containing anhydrous calcium sulfate. Commercial reagents 
were purified according to the methods compiled by Armengo and Perrin.11 Reactions 
were monitored by thin-layer chromatography on Merck Siligel 60-F254. Compounds 
were visualized with UV lamp (254 nm) and stained with ceric ammonium molybdate 
solution.  Column chromatography was carried out in accordance with the methods of 
Still12 using EMD-Merck silica gel 60, 230-400 mesh ASTM. For dCA-coupling 
reactions, the reaction progress is monitored by analytical HPLC, and the reaction is 
ultimately quenched with a threefold (volume) excess of 1:1 acetonitrile: 10 mM aq. 
AcOH, which is then directly loaded onto the preparative HPLC. The standard HPLC 
method runs a gradient of 95:5 to 0:100 of 25 mM ammonium acetate, pH = 4.5: 
acetonitrile over a run time of 15 minutes. The product fraction(s) are then lyophilized to 
dryness. 1H and 13C NMR spectra were acquired on a Varian Mercury 300 MHz 
spectrometer. High-resolution mass spectrometry was performed on a JEOL JMS-600H 
HRMS using an Electrospray Ion Source. Copies of NMR spectra of the synthesized 
compounds can be found in the supporting information section of our submission of this 
work to the Journal of Biological Chemistry.1 
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Chemistry—Synthesis 
 
Glycerate methyl ester (22). Glycerate, calcium salt dihydrate (286 mg, 2.0 mmol) was 
measured into a 100 mL round-bottomed flask.  Methanol (40 mL) and toluene (10 mL) 
were then added, followed by HCl (1 mL, 12 N, 12 mmol). The mixture was stirred under 
reflux for 6 h, at which point the solvent was removed in vacuo to give 464 mg of a crude 
residue that was moved directly forward into the next step. 
 
2,3-di-tert-butyldimethylsilylglycerate methyl ester (23). Glycerate methyl ester (464 
mg crude residue, above) was dissolved in DMF (6 mL) in a 2 dram vial.  TBSCl (906 
mg, 6 mmol) and imidazole (544 mg, 8 mmol) were then added, and the reaction was 
stirred at room temperature for 12 h, at which point the reaction was concentrated in 
vacuo to ca. 1 mL, and dichloromethane (10 mL) was added.  The precipicate was 
removed by filtration, and the filtrate was reduced in vacuo and purified by flash 
chromatography on silica (5% EtOAc in hexanes) to yield 421 mg (60% over 2 steps) 
2,3-di-tert-butyldimethylsilylglycerate methyl ester. 1H NMR (300 MHz, CDCl3) δ 4.27 
(dd, 1H, J = 5.2, 6.2 Hz), 3.80 (dd, 1H, JAB = 9.9 Hz, JAX = 5.2 Hz), 3.73 (dd, 1H, JAB = 
9.9 Hz, JAX = 6.6 Hz), 3.70 (s, 3H), 0.88 (s, 9H), 0.85 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H), 
0.03 (s, 3H), 0.02 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 172.71, 74.21, 66.16, 51.99, 
26.04, 25.94, 18.57, 18.52, -4.86, -4.87, -5.16, -5.25. LRMS (ES+) calculated for 
[C16H36NaO4Si2] ([M+Na]+) 371.2, found 371.1. 
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2,3-di-tert-butyldimethylsilylglycerate cyanomethyl ester (25). 2,3-di-tert-
butyldimethylsilylglycerate methyl ester (100 mg, 0.29 mmol) was measured into a 2 
dram vial.  Diethyl ether (3 mL) was added to dissolve the starting material, followed by 
potassium trimethylsilynoate (40.7 mg, 0.29 mmol).  After 18 h, the potassium salt was 
isolated by filtration, washed with 2 x 1 mL ether, and dried in vacuo.  The solid was then 
resuspended in chloroacetonitrile (3 mL) by sonication, and allowed to stir at room 
temperature for 6 hours.  The reaction was then filtered through a plug of silica to yield 
the pure product as a colorless liquid: 66.7 mg (62% over 2 steps) 2,3-di-tert-
butyldimethylsilylglycerate cyanomethyl ester. 1H NMR (300 MHz, CDCl3) δ 4.75 (s, 
2H), 4.35 (t, 1H, J = 5.4 Hz), 3.81 (d, 2H, J = 5.4 Hz), 0.90 (s, 9H), 0.87 (s, 9H), 0.10 (s, 
3H), 0.08 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 170.82, 
114.24, 73.78, 65.92, 48.62, 26.01, 25.87, 18.48, -4.86, -4.90, -5.21, -5.24. HRMS 
(FAB+) calculated for [C17H36NO4Si2] ([M+H]+) 374.2183, found 374.2181. 
 
2,3-di-tert-butyldimethylsilylglycerate dCA ester (26). 2,3-di-tert-
butyldimethylsilylglycerate cyanomethyl ester (8.9 mg, 24 umol) and dCA*2.4 TBA (8.2 
mg, 6.5 umol) were measured into a 1 dram vial. DMF (0.8 mL) was added, and the 
reaction was allowed to stir at room temperature for 24 h, at which point the reaction was 
quenched and purified by HPLC to yield 0.74 µmol (11%) 2,3-di-tert-
butyldimethylsilylglycerate dCA ester. LRMS (ESI-) calculated for [C34H57N8O16P2Si2]- 
([M-H]-) 951.3, found 951.4. 
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α-Hydroxy serine-dCA (2). 2,3-di-tert-butyldimethylsilylglycerate dCA ester (0.73 
umol) in a 15 mL falcon tube was dissolved in water (0.2 mL), THF (0.2 mL) and AcOH 
(0.6 mL) and shaken at 37 °C for 24 h, at which point the reaction was lyophilized to give 
0.24 µmol (34%) α-Hydroxy serine-dCA. LRMS (ESI-) calculated for [C22H29N8O16P2]- 
([M-H]-) 723.1, found 723.4. 
 
4-amido-2-hydroxybutyrate methyl ester (5). 4-amido-2-hydroxybutyric acid (133 mg, 
1.0 mmol)13 was measured into a 50 mL round-bottomed flask.  Methanol (20 mL) and 
toluene (4 mL) were added, followed by HCl (0.5 mL, 12 N).  The solution was refluxed 
for 3 h, at which point the solvent was removed in vacuo.  The residue was resuspended 
in acetone (5 mL) and filtered to remove the solids.  The filtrate was reduced in vacuo to 
give a crude yield of 145 mg.  This residue was purified by flash chromatography on 
silica (50% acetone in dichloromethane) to yield 57.2 mg (39%) of the desired product as 
a white crystalline solid (note: the product was very difficult to elute off the silica). 1H 
NMR (300 MHz, acetone-d6) δ 7.05 (bs, 1H), 6.56 (bs, 1H), 4.73 (bs, 1H), 4.49 (m, 1H), 
3.68 (s, 3H), 2.54-2.69 (m, 2H). 13C NMR (75 MHz, acetone-d6) δ 174.02, 172.52, 68.00, 
51.56, 39.58. 
 
4-amido-2-tert-butyldimethylsiloxybutyrate methyl ester (6). 4-amido-2-
hydroxybutyrate methyl ester (54 mg, 0.37 mmol) was measured into a 1 dram vial.  
DMF (350 µL) was added to dissolve the starting material, followed by TBSCl (76 mg, 
0.50 mmol) and imidazole (56 mg, 0.82 mmol).  The solution was stirred at room 
temperature for 1 h, at which point dichloromethane (3.5 mL) was added.  After 5 
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minutes stirring, a white precipitate fell out and was removed by filtration through a silica 
plug.  The filtrate was reduced in vacuo and purified by flash chromatography on silica 
(7% acetone in dichloromethane) to yield 87.3 mg (91%) 4-amido-2-tert-
butyldimethylsiloxybutyrate methyl ester. 1H NMR (300 MHz, acetone-d6) δ 6.33 (bs, 
1H), 6.16 (bs, 1H), 4.57 (m, 1H), 3.67 (s, 3H), 2.51-2.66 (m, 2H), 0.84 (s, 9H), 0.06 (s, 
3H), 0.03 (s, 3H). 13C NMR (75 MHz, acetone-d6) δ 173.18, 172.44, 69.40, 52.39, 41.50, 
25.81, 18.38, -4.89, -5.37. LRMS (ESI+) calculated for [C11H24NO4Si]+ ([M+H]+) 262.1, 
found 261.9. 
 
4-amido-2-tert-butyldimethylsiloxybutyrate cyanomethyl ester 9 (and regioisomer 
8). 4-amido-2-tert-butyldimethylsiloxybutyrate methyl ester (46 mg, 0.18 mmol) was 
measured into a 2 dram vial.  Methanol (2 mL) was added, and the vial was cooled to 
0 °C.  Aqueous lithium hydroxide (0.89 mL, 0.2 N, 0.18 mmol) was added over a period 
of 1 h, and the solution was allowed to reach room temperature (note: at the end of the 
addition period, TLC indicated the cyclic imide as the dominant species in the reaction 
mixture).  After 5 days stirring, the reaction mixture was flash-frozen and lyophilized to 
dryness.  Chloroacetonitrile (2 mL) and DMF (2 mL) were then poured over the dry salt, 
which slowly dissolved under stirring and sonication.  After 4 h stirring at room 
temperature, the solvent volume was concentrated to ca. 0.5 mL; dichloromethane (4 mL) 
was then added, and the solids were removed by filtration through a silica plug.  The 
filtrate was then reduced in vacuo and purified by flash chromatography (20% acetone in 
dichloromethane) to yield 14.8 mg (30%) 4-amido-2-tert-butyldimethylsiloxybutyrate 
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cyanomethyl ester and 3.5 mg (7%) of the regioisomer 4-amido-3-tert-
butyldimethylsiloxybutyrate cyanomethyl ester. 
 
4-(N-triisopropylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate methyl ester (11). 
4-amido-2-tert-butyldimethylsiloxybutyrate methyl ester (522 mg, 2.0 mmol) was 
measured into a 25 mL round-bottomed flask.  Dichloromethane (4 mL) was added, and 
the flask was cooled to -10 °C. 2,6-Lutidine (465 µL, 4.0 mmol) was added in one 
portion, followed by the dropwise addition of triisopropylsilyl triflate (645 µL, 2.4 
mmol).  After 1 h stirring at 0 °C, toluene (8 mL) was added, and the solids were 
removed by filtration.  The filtrate was reduced in vacuo and purified by flash 
chromatography on silica (15% EtOAc in hexanes) to yield 733.9 mg (87.8%) 4-(N-
triisopropylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate methyl ester. 1H NMR (300 
MHz, CDCl3) δ 5.67 (bs, 1H), 4.51-4.56 (m, 1H), 3.69 (s, 3H), 2.72 (d, 2H, J = 5.1 Hz), 
1.17-1.31 (m, 3H), 1.02 (dd, 18H, J = 7.5, 2.4 Hz), 0.88 (s, 9H), 0.12 (s, 3H), 0.07 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 175.12, 172.97, 69.34, 52.35, 42.99, 25.83, 18.44, 
18.38, 18.37, 11.54, -4.73, -5.43. LRMS (ESI+) calculated for [C20H44NO4Si2]+ ([M+H]+) 
418.3, found 418.3. 
 
4-(N-triisopropylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate cyanomethyl ester 
(13). Potassium trimethylsilenote (71 mg, 0.5 mmol) was measured into a 2 dram vial, 
and diethyl ether (2.5 mL) was added. A solution of 4-(N-triisopropylsilyl)-amido-2-tert-
butyldimethylsiloxybutyrate methyl ester (209 mg, 0.5 mmol) in ether (2.5 mL) was then 
added dropwise to this stirred suspension at 0 °C.  After 9 h the solvent was removed in 
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vacuo and DMF (2 mL) was added to dissolve the residue.  Chloroacetonitrile (2 mL) 
was then added, and the vial was stirred at room temperature for 10 h; the solvent was 
then removed in vacuo, and the residue was purified by flash chromatography on silica 
(12%  16% EtOAc in hexanes) to yield 74.2 mg (34%) 4-(N-triisopropylsilyl)-amido-
2-tert-butyldimethylsiloxybutyrate cyanomethyl ester. 1H NMR (300 MHz, CDCl3) δ 
5.29 (bs, 1H), 4.64-4.83 (m, 3H), 2.69-2.82 (m, 2H), 1.20-1.33 (m, 3H), 1.05 (d, 18H, J = 
7.5 Hz), 0.90 (d, 9H, J = 1.5 Hz), 0.14 (d, 3H, J = 1.5 Hz), 0.10 (d, 3H, J = 1.5 Hz). 13C 
NMR (75 MHz, CDCl3) δ 174.33, 171.29, 114.10, 69.03, 48.93, 42.94, 25.74, 18.33, 
17.87, 11.45, -4.82, -5.36. HRMS (FAB+) calculated for [C21H43N2O4Si2]+ ([M+H]+) 
443.2761, found 443.2765. 
 
4-(N-triisopropylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate dCA ester (14). 4-
(N-triisopropylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate cyanomethyl (11 mg, 25 
umol) and dCA*2.4 TBA (6 mg, 4.8 µmol) were measured into a 1 dram vial. DMF (0.8 
mL) was added, and the reaction was allowed to stir at room temperature for 6 h, at 
which point the reaction was quenched and purified by HPLC to yield 0.14 µmol (2.9%) 
4-(N-triisopropylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate dCA ester (a significant 
amount of free dCA was also present). LRMS (ESI-) calculated for [C38H64N9O16P2Si2]- 
([M-H]-) 1020.3, found 1020.5. 
 
α-Hydroxy asparagine-dCA (1). 4-(N-triisopropylsilyl)-amido-2-tert-butyldimethyl-
siloxybutyrate dCA ester (0.14 µmol) in a 15 mL falcon tube was dissolved in water (0.3 
mL), THF (0.3 mL), and AcOH (0.9 mL) and shaken at 37 °C for 42 h, at which point the 
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reaction was lyophilized to give 0.12 µmol (86%) α-Hydroxy asparagine-dCA. LRMS 
(ESI-) calculated for [C23H30N9O16P2]- ([M-H]-) 750.1, found 750.5. 
 
4-(N-tert-butyldiphenylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate methyl ester. 
4-amido-2-tert-butyldimethylsiloxybutyrate methyl ester (92.5 mg, 0.35 mmol) and 
dimethylaminopyridine (4 mg, 0.035 mmol) were measured into a 1 dram vial.  
Dichloromethane (0.7 mL) was added, followed by triethylamine (99 µL, 0.71 mmol).  
The vial was cooled to 0 °C and TBDPSCl (118 µL, 0.46 mmol) was added dropwise.  
After 7 h the solvent was removed in vacuo, and the residue was purified by flash 
chromatography on silica (12%  20% EtOAc in hexanes) to yield 125.3 mg (71%) 4-
(N-tert-butyldiphenylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate methyl ester. 1H 
NMR (300 MHz, CDCl3) δ 7.63-7.70 (m, 4H), 7.34-7.42 (m, 6H), 6.32 (bs, 1H), 4.62 (m, 
1H), 3.73 (s, 3H),  2.85 (m, 2H), 1.10 (s, 9H), 0.89 (s, 1H), 0.14 (s, 3H), 0.09 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 174.86, 173.06, 135.63, 135.57, 135.08, 132.82, 132.74, 
129.89, 129.74, 127.96, 69.40, 52.47, 43.18, 27.85, 26.82, 25.88, 18.50, -4.67, -5.36. 
LRMS (ESI+) calculated for [C27H42NO4Si2]+ ([M+H]+) 500.3, found 500.4. 
 
4-(N-tert-butyldimethylsilyl)-amido-2-tert-butyldimethylsiloxybutyrate methyl ester. 
4-amido-2-tert-butyldimethylsiloxybutyrate methyl ester (45.6 mg, 0.18 mmol) and 
dimethylaminopyridine (2 mg, 0.018 mmol) were measured into a 2 dram vial.  
Dichloromethane (0.35 mL) and triethylamine (49 µL, 0.35 mmol) were added to 
dissolve the solids, and TBSCl (32 mg, 0.21 mmol) was then added.  The reaction was 
stirred at room temperature for 90 minutes, then the solvent was removed in vacuo, and 
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the residue was purified by flash chromatography on silica (12%  20% EtOAc in 
hexanes) to yield 43.3 mg (66%) 4-(N-tert-butyldimethylsilyl)-amido-2-tert-
butyldimethylsiloxybutyrate methyl ester. 1H NMR (300 MHz, CDCl3) δ 5.56 (bs, 1H), 
4.54-4.60 (m, 1H), 3.70 (s, 3H),  2.57-2.74 (m, 2H), 0.89 (d, 18H), 0.20 (s, 3H), 0.18 (s, 
3H), 0.11 (s, 3H), 0.08 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 175.22, 173.13, 69.54, 
52.34, 43.58, 26.31, 25.86, 18.42, 17.30, -4.77, -4.88, -5.05, -5.36. LRMS (ESI+) 
calculated for [C17H38NO4Si2]+ ([M+H]+) 376.2, found 376.2. 
 
4-amido-2-(o-nitroveratrylamino)-butyrate cyanomethyl ester (18). Compound 17 
(103 mg, 0.28 mmol) was measured into a 2 dram vial. DMF (4 mL) was added, followed 
by chloroacetonitrile (1 mL) and TEA (60 µL, 0.43 mmol) was added in portions over 3 h 
at room temperature.  The reaction was then poured over 0.5 N aq. HCl (75 mL) and 
extracted with 5 x 20 mL ethyl acetate. The organic extracts were concentrated in vacuo 
to ca. 5 mL, at which point the crystalline white product was isolated by filtration. Yield 
was 84 mg (74 %). HRMS (FAB+) calculated for [C16H19N4O9]+ ([M+H]+) 411.1152, 
found 411.1143. 
  
4-(N-triisopropylsilyl)-amido-2-(o-nitroveratrylamino)-butyrate cyanomethyl ester 
(19). Compound 18 (20 mg, 0.05 mmol) was measured into a 2 dram vial and suspended 
in DCM (2 mL). Addition of TIPSOTf (18 µL, 0.07 mmol), followed by slow addition of 
lutidine (8 µL, 0.07 mmol), caused the starting material to dissolve within 30 min. The 
reaction mixture was then reduced in vacuo and purified by chromatography (silica, 
acetone) to give 18.9 mg (68 %) of a white crystalline solid. 1H NMR (300 MHz, 
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acetone-d6) δ 7.73 (s, 1H), 7.23 (s, 1H), 6.99 (d, 1H, J = 8.7 Hz), 6.39 (s, 1H), 5.40-5.56 
(m, 2H), 4.98 (m, 2H), 4.66-4.76 (m, 1H), 3.98 (s, 3H), 3.95 (s, 3H), 2.89-3.11 (m, 2H), 
1.22-1.37 (m, 3H), 1.07 (d, 18H). 13C NMR (75 MHz, acetone-d6) δ 176.33, 171.55, 
156.54, 155.02, 149.27, 129.21, 115.79, 110.87, 109.01, 64.03, 56.83, 56.65, 51.81, 
50.23, 39.36, 18.29, 12.31, -4.48. HRMS (FAB+) calculated for [C25H39N4O9Si]+ 
([M+H]+) 567.2486, found 567.2503. 
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Section 1: Chapter 4 
 
 
 
Probing a Key Hydrogen Bond in the Nicotinic Acetylcholine Receptor 
through Mutant Cycle Analysis1 
 
 
Abstract: Though much is now known about the structure of the nicotinic 
acetylcholine receptor (nAChR) binding site, relatively little is understood about how the 
binding event is communicated to the channel gate, causing the pore to open. Here we 
use mutant cycle analysis with the novel unnatural residue α-hydroxyserine (Sah) to 
identify a key hydrogen bond near the binding site that is involved in the gating pathway. 
This hydrogen bond is between the backbone N-H of αS191 in loop C and the sidechain 
of γD174/δD180—which had originally been identified as a key binding residue for 
cationic agonists. 
 
 The Cys-loop family of ligand-gated ion channels is involved in mediating fast 
synaptic transmission throughout the central and peripheral nervous systems.2 These 
neuroreceptors are among the molecules of learning, memory, and sensory perception, 
and they are implicated in numerous neurological disorders, including Alzheimer’s 
disease, Parkinson’s disease, and schizophrenia.  The muscle nicotinic acetylcholine 
receptor (nAChR) is arguably the best-studied member of the Cys-loop family. This 
heteropentameric receptor is composed of homologous, but functionally distinct, subunits 
arranged symmetrically around a central ion-conducting pore with the stoichiometry 
α2βγδ. The agonist binding sites are located at the interfaces between the α:γ and α:δ 
subunits. The binding of two agonist molecules induces a conformational change that 
leads to the opening of the ion channel. 
 It is now widely appreciated that a tryptophan residue (αW149) plays a key role 
in neurotransmitter binding by forming a cation-π interaction with the quaternary 
ammonium group of acetylcholine,3 a result supported by structural data. However, many 
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other important residues in the immediate vicinity of the binding site have been identified. 
In a classic experiment on the Torpedo nAChR (a close homologue of the muscle 
subtype), Czajkowski and Karlin concluded that an aspartate (γD174/δD180) from the 
complementary binding subunit could come within 9 Å of the agonist binding site.4 
Mutation of this residue severely impacted receptor function, leading to a proposal that 
the negative charge of this aspartate interacted with the positive charge of the agonist.5 
Subsequently, however, both the crystal structure of acetylcholine-binding protein 
(AChBP, a soluble protein homologous to the extracellular domain of the nAChR)6 and 
the 4 Å cryo-EM structure of Torpedo nAChR7 showed that this residue is positioned 
quite far from the agonist binding site (Figure 4.1). Single-channel studies suggest that 
this residue is primarily important for ligand-induced channel gating rather than agonist 
binding.8 
 γD174/δD180 is part of loop F, the 
most remote of the six loops originally 
proposed by Changeux to contribute to the 
agonist binding site, 9  In the carbamyl-
choline-bound AChBP structure, 10  a 
different F loop anionic residue, 
γE176/δE182 (AChBP E163), is 
positioned near loop C of the agonist 
binding site (Figure 4.1).  Specifically, 
γE176/δE182 is within hydrogen bonding distance of the backbone N-H at αS191, which 
is located on the C loop between the aromatic binding box residue αY190 and the vicinal 
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disulfide formed by αC192 and αC193. Loop F is generally disordered in the AChBP 
and nAChR structures, and hydrogen-deuterium exchange mass spectrometry on AChBP 
reveals that loop F and loop C are the most conformationally dynamic segments of the 
protein.11 It is generally accepted that agonist binding draws loop C inward, capping the 
aromatic binding pocket.12 In contrast, crystal structures of AChBP with antagonists 
bound reveal loop C pulled away from the agonist binding site. Distinctions between 
antagonist- and agonist-induced motions have also been observed in loop F.13 As such, 
many investigators favor a gating model involving a contraction of the agonist binding 
site around an agonist molecule that is largely mediated by movements in loops C and F, 
though little is known about the nature of the specific interactions involved in this 
systolic motion. 
 In the process of probing the backbone flexibility surrounding the nAChR binding 
box, we mutated αS191 to α-hydroxyserine (Sah). This produces an ester backbone 
linkage at this position, while preserving the side chain. Along with increasing backbone 
flexibility, this mutation removes the hydrogen bond-donating N-H group and replaces it 
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with a non-hydrogen bond-donating O (Figure 4.2). We have performed similar backbone 
mutations at several positions in the nAChR, and typically the consequences are not 
dramatic.14  However, at αS191, this subtle mutation leads to a 40-fold increase in EC50 
(Table 4.1). We also made alanine and α-hydroxyalanine (Aah) mutations at this site.  
The side chain mutation alone had minimal impact on receptor function, producing no 
shift in EC50. However, receptor function of the αS191Aah mutant was dramatically 
impaired relative to αS191Ala, confirming that the backbone—and not the side chain—at 
αS191 is important for receptor function. We also made an analogous αAsn94Nah 
mutation at a site that is similarly adjacent to the binding box, and the EC50 shift from 
wild type was minor. 
 To evaluate the potential hydrogen bond from αS191 to γE176/δE182, we made 
several mutations at this glutamate. Surprisingly, all mutations have minimal impact, 
suggesting no critical role for this residue.  Another nearby loop F glutamate residue, 
γE169/δE175, was also evaluated.  Again, no significant impact was seen.  
 In sharp contrast, even the subtlest mutations at γD174/δD180 produce large 
effects upon receptor function, a result that others have also seen.15 We first studied 
asparagine, glutamate, and glutamine mutations at this site.  The γD174E/δD180E mutant 
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exhibits a modest ~threefold decrease in EC50. However, the γD174N/δD180N and 
γD174Q/δD180Q mutants produce substantial (> 100-fold) changes to the EC50.  
 Fundamentally, the results of these conventional mutations strongly implicate the 
side chain of γD174/δD180 in an electrostatic interaction, such as an ion pair or hydrogen 
bond.  However, changing the side chain functionality from a carboxylate to an amide not 
only neutralizes the charge on the side chain, it also desymmetrizes it and introduces a 
potential hydrogen bond donor.  To better understand the role of γD174/δD180, we 
incorporated two unnatural amino acids. 
 Nitrohomoalanine (Nha) is an analogue of glutamate that contains a nitro (NO2) 
group, which is isosteric and isoelectronic to a carboxylate, but it has no charge and is a 
much weaker hydrogen bond acceptor (Figure 4.2a). 16  Incorporation of Nha at 
γD174/δD180 yields a slightly less dramatic effect than the γD174N/δD180N and 
γD174Q/δD180Q mutants, producing a 24-fold shift in EC50 relative to γD174E/δD180E. 
Thus, charge neutralization at this site significantly affects receptor function but cannot 
fully account for the EC50 shift seen in the γD174N/δD180N and γD174Q/δD180Q 
mutants. 
 The second unnatural amino acid analogue incorporated at γD174/δD180 was 2-
amino-4-ketopentanoic acid (Akp). Akp is isoelectronic to Asp, but possesses a methyl 
ketone functionality in place of the carboxylate. As such, Akp is a desymmetrized 
analogue of Asp—similar to Asn—but it has different electrostatic properties (less polar, 
weaker hydrogen bond acceptor, and cannot donate a hydrogen bond).  When Akp is 
incorporated at γD174/δD180, its effect upon receptor function is roughly as deleterious 
as the Asn mutation. Mutations at individual binding sites (α2βγD174Nδ and 
  
53 
α2βγδD180N) showed substantial (~50-
fold) and approximately equivalent 
increases in whole cell EC50. 
 Mutant cycle analyses were 
performed between several of the side 
chain mutations at γD174/δD180 and 
the αS191Sah mutation (Figure 4.3).  
Briefly, mutant cycle analysis is used to 
determine the pairwise interaction 
energy between two residues in a 
protein using the equation given in 
Figure 4.3.  If the two residues do not interact, the change in free energy for the 
simultaneous mutation of both residues should simply be the sum of the free energy of 
each of the individual mutations. However, for residues that interact, the change in free 
energy for the double mutation will be non-additive.  EC50-based mutant cycle analysis 
has been used to investigate interactions 
in Cys-loop receptors by other 
researchers.17 
 Lengthening the side chain 
(γD174E/δD180E) has no impact on the 
interaction between these two residues 
(ΔΔG = 0.12 kcal/mol; Figure 4.4). In 
contrast, mutant cycle analysis between 
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γD174N/δD180N and αS191Sah indicates a large energetic coupling (ΔΔG = 2.1 
kcal/mol). A smaller but still quite significant effect is seen for the mutant cycle analysis 
between γD174Nha/δD180Nha and αS191Sah (ΔΔG = 1.4 kcal/mol). Mutant cycle 
analyses of γD174N/δD180N with αS191A and αS191Aah further support the 
conclusion that the interaction between these residues involves the backbone of αS191 
and not the side chain (αS191Ala: ΔΔG = 0.25; αS191Aah: ΔΔG = 2.3 kcal/mol). 
Comparable mutant cycle analyses of the two glutamates of loop F, γE176/δE182 and 
γE169/δE175, with αS191Sah showed no significant coupling. 
 
 The AChBP crystal structures transformed the study of nAChRs by providing 
high-resolution structural data about the ligand binding domain of these proteins.  In 
addition to refining our existing structural knowledge of the receptor—obtained from 
decades of careful biochemical research—it served as a valuable starting point for new 
structure-function studies on the receptor.  However, AChBP is not a ligand-gated ion 
channel and, in fact, shares less than 25% homology with its nearest Cys-loop relative, 
the α7 nAChR. As such, some fundamental structural differences presumably exist 
between AChBP and actual Cys-loop receptors, particularly pertaining to residues 
involved in mediating communication between the binding site and the ion channel pore. 
 Arguably the biggest discrepancy between the AChBP structures and prior 
biochemical studies of the nAChR concerns the loop F residue γD174/δD180.  A 
remarkable cross-linking study in the Torpedo nAChR indicated that this residue can 
come within 9 Å of the vicinal disulfide on the C loop, located at the heart of the agonist 
binding site.18 Yet, in AChBP the residue that aligns with γD174/δD180 is not at all near 
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the agonist binding site. In addition, the cryo-EM structure of the Torpedo nAChR, which 
is believed to be in the desensitized or closed state, places this residue tucked deeply 
inside a β-sheet-lined hydrophobic pocket, over 15 Å from loop C. 
 While γD174/δD180 is remote to the agonist binding site in AChBP, another loop 
F anionic residue, γE176/δE182, appears to make a hydrogen bond to a backbone N-H 
that is integral to the aromatic box of the agonist binding site when the agonist 
carbamylcholine is bound.  Using nonsense suppression methodology, we have been able 
to specifically remove the backbone N-H in question by replacing αS191 with its α-
hydroxy analogue. Consistent with the AChBP images, this subtle structural change has a 
large effect on receptor function, suggesting that a hydrogen bond to this moiety is 
important. However, consistent with prior mutational analyses, we find that γE176/δE182 
does not play a large role in receptor function. This suggests that AChBP provides only 
an imperfect model of the muscle nAChR in this region. Given that the sequence 
alignment in this region shows a number of insertions in nAChR relative to AChBP—
combined with the fact that the F loop is believed to be involved in gating the nAChR 
(AChBP does not gate)—it is not surprising that AChBP would be an unreliable model 
here. 
 Our results indicate that the hydrogen-bonding partner for the backbone N-H of 
αS191 in the nAChR is instead the side chain of γD174/δD180. Based on the available 
structural and functional data, we suggest that this hydrogen bond exists in the open state 
only. As others have seen, a number of mutations of this side chain profoundly affect 
receptor function. Here we employ several relatively subtle mutations.  The fact that 
substantial functional consequences are seen suggests a precise structural role for this 
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side chain in at least one state crucial for activating the channel. Furthermore, all 
mutations at γD174/δD180 that significantly impact function also show strong coupling 
to the αS191Sah backbone mutation via mutant cycle analysis.  The nature of the 
coupling is expected from the hydrogen bonding model: mutation at either site has a 
strong effect; however, once the αS191Sah mutation is introduced—removing any 
possible hydrogen bonding interaction—mutations at γD174/δD180 have a much smaller 
impact. Interestingly, no specific role for the side chain of αS191 is found, as the 
αS191A mutant gives essentially wild-type behavior.19 However, when the alanine side 
chain is combined with the α-hydroxy backbone mutation, the same coupling to 
γD174/δD180 is observed. 
 We propose that the movement of loop F of the complementary subunit from a 
position remote to the agonist binding site to one of close proximity to loop C of the 
principal subunit is a key early structural change associated with nAChR gating.  Driving 
this structural reorganization is the formation of a hydrogen bond between the side chain 
of γD174/δD180 and the backbone N-H of αS191. In the closed state of the wild-type 
receptor, αS191 and the C loop project out into solution, away from the bulk of the 
receptor, while γD174/δD180 of the F loop projects deep within a hydrophobic cavity. 
Though the energetic desolvation penalty of burying a charged residue within a 
hydrophobic cavity is significant,20 it alone is apparently not sufficient to overcome other 
structural elements that bias this conformation of the F loop. However, agonist binding 
induces a centripetal movement of the C loop, bringing the backbone N-H of αS191 in 
closer proximity to the F loop. This structural change makes possible a hydrogen bond 
between γD174/δD180 and the C loop backbone. We hypothesize that the formation of 
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this hydrogen bond, along with the energetic solvation benefit of moving γD174/δD180 
into an aqueous environment, provides sufficient driving force to move γD174/δD180 out 
of its pocket, inducing a movement of the F loop toward the C loop.21 This structural 
rearrangement of loop F contributes to the gating pathway. Using rate-equilibrium free 
energy relationships, Auerbach and coworkers have also concluded that γD174/δD180 
moves early in the gating process.22 
 Our results provide an explanation for the cross-linking studies of Czajkowski and 
Karlin,23 and they are not in conflict with available structural information. Though the 
cryo-EM images of the Torpedo receptor show greater than 20 Å separation between 
αS191 and γD174/δD180 in the closed state, the distance of less than 9 Å that is 
suggested by the crosslinking studies is still plausible, provided that the residues are free 
to move closer. A comparison of AChBP structures with and without agonist bound 
likewise shows that motions of loops C and F are the dominant structural rearrangements 
that occur when agonist binds.  The fact that the hydrogen bond acceptor in loop F differs 
between AChBP and nAChR is not surprising, given that loop F is strongly implicated in 
nAChR gating and AChBP did not evolve to have a gating function. 
 This model is also consistent with the γ174/δ180 mutants described here. 
Lengthening the sidechain of this key F loop residue (γD174E/δD180E) effects a modest 
improvement in receptor function, either because the longer sidechain can more easily 
reach its αS191 hydrogen bonding partner, or because it fits more poorly in the 
hydrophobic pocket, destabilizing the closed state. Any mutation that eliminates side 
chain charge has a significant impact on function, which is expected, given that these 
mutant side chains are poorer hydrogen bond acceptors and that they experience a much 
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lower energetic solvation benefit upon moving from the hydrophobic pocket into an 
aqueous environment.  
 In conclusion, mutant cycle analysis involving a novel backbone mutant has 
identified an important interaction between an F loop residue that has long been thought 
to contribute to receptor function and the peptide backbone of loop C.  The hydrogen 
bond between the side chain of γD174/δD180 and the backbone of αS191 likely forms 
upon agonist binding and is part of the agonist-induced conformational changes that lead 
to channel opening.  Along with contributing new insights into the gating pathway of the 
nAChR, our results reconcile a long-standing discrepancy between early biochemical 
studies of the receptor and structural models from the AChBP systems. 
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Biology—Mutagenesis 
 
Conventional mutagenesis and unnatural mutagenesis, with the site of interest mutated to 
either an amber stop codon or a four-base frameshift codon (at αS191), were achieved by 
a standard Stratagene QuikChange protocol. Sequencing through both strands confirmed 
the presence of the desired mutation. Mouse muscle embryonic nAChR in the pAMV 
vector was used.  All the mutations were made in the presence of a background 
transmembrane mutation (βL9’S) that lowers whole-cell EC50.24 In addition, the α-
subunits contain an HA epitope in the M3-M4 cytoplasmic loop for Western blot studies. 
Control experiments show that this epitope does not detectably alter EC50.  mRNA was 
prepared by in vitro runoff transcription using the Ambion (Austin, TX) T7 mMessage 
mMachine kit. For conventional mutants, a total of 2.0-4.0 ng of mRNA was injected in a 
ratio of 2:1:1:1 of α:β:γ:δ.  For suppression with unnatural amino and hydroxy acids, a 
total of 4.0 ng of mRNA was injected in an α:β:γ:δ subunit ratio of 10:1:1:1. Typically, 
25 ng of tRNA was injected per oocyte along with mRNA in a ratio of 1:1 with a total 
volume of 50 nL/cell. As a negative control for suppression, truncated 74-nucleotide 
tRNA or truncated tRNA ligated to dCA was co-injected with mRNA in the same manner 
as fully charged tRNA. Data from experiments where currents from these negative 
controls were greater than 10% of the experimental were excluded. Frameshift 
suppression at αS191 was used for simultaneous incorporation of two unnatural 
residues.25 
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Biology—Electrophysiology 
The function of mutant receptors was evaluated using two-electrode voltage clamp.  
Stage V-VI oocytes of Xenopus laevis were employed. Oocyte recordings were made 12-
48 h postinjection in two-electrode voltage clamp mode using the OpusXpress 6000A 
instrument (Axon Instruments, Union City, CA). Oocytes were superfused with a Ca2+-
free ND96 solution at flow rates of 1 mL/min before application, 4 mL/min during drug 
application, and 3 mL/min during wash. Holding potential was -60 mV. Data were 
sampled at 125 Hz and filtered at 50 Hz. Drug applications were 15 s in duration. 
Acetylcholine chloride was purchased from Sigma/Aldrich/RBI. Solutions ranging from 
0.01 mM to 5000 mM were prepared in Ca2+-free ND96 from a 1 M stock solution.  
Dose-response data were obtained for a minimum of 8 concentrations of agonists and for 
a minimum of five cells. Dose-response relations were fitted to the Hill equation to 
determine EC50 and Hill coefficient values. The dose-response relations of individual 
oocytes were examined and used to determine outliers. The reported EC50 values are from 
the curve fit of the averaged data. 
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Section 2: Chapter 5 
 
 
 
The Room Temperature Wolff-Kishner-Type Reductive Deoxygenation 
of Acyl Phosphonates: A One-Pot Transformation of Carboxylic Acids 
into Alkyl Phosphonates1 
 
 
Abstract: The reductive deoxygenation of acyl phosphonates using a Wolff-Kishner-
like sequence is described. This transformation allows direct access to alkyl 
phosphonates from acyl phosphonates at room temperature. The method can be 
combined with acyl phosphonate synthesis into a one-pot, four-step procedure for the 
conversion of carboxylic acids into alkyl phosphonates. 
 
 Phosphonates are a key functional group in both organic synthesis and biological 
chemistry.2 In synthesis, they are a direct precursor of olefins through the Horner-
Wadsworth-Emmons reaction.3 In biological chemistry, their unique structure and charge 
distribution give them an important role in pharmaceuticals4 and phosphoester mimicry.5 
Phosphonates have traditionally been accessed through the Arbuzov reaction:6,7 a double 
SN2 process between an alkyl halide and a trialkylphosphite (Scheme 5.1), and this 
remains the most commonly employed route today. Notable exceptions include aryl/vinyl 
phosphonates,8 whose corresponding halides cannot readily participate in SN2 reactions, 
and α-hydroxyl/α-amino 
phosphonates,9 whose 
corresponding halides are 
unstable. 
 Despite its prevalence, the Arbuzov reaction has two key drawbacks. First, the 
elevated temperatures typically required limit the scope of substrates suitable for the 
reaction. Second, the reaction generates one equivalent of alkyl halide, which can react 
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Scheme 5.1. The Arbuzov reaction.
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with the phosphite under the reaction conditions to reduce yield and reaction efficiency. 
A modification using dialkylphosphite salts instead of trialkylphosphites eliminates the 
problem of new alkyl halide generation, but the yields are typically poorer, and this 
strategy is much less used.10 A number of other strategies for alkyl phosphonate synthesis 
have been developed,11,12 most notably the transition metal-mediated 
hydrophosphonylation of olefins with cyclic five-membered hydrogen phosphonates.13 
Yet even this reaction is limited by the phosphite component scope and prolonged 
heating. Here we present a room-temperature alternative to the Arbuzov reaction that 
allows for the synthesis of phosphonates from carboxylic acids. 
 We began with the observation that the Arbuzov reaction of acyl halides is 
strikingly mild in comparison to the alkyl variant, often going to completion in several 
minutes at room temperature.14 Second, we noted that these acyl phosphonates can form 
isolable hydrazones,15 in contrast to most other carboxylic acid derivatives.  This led us to 
consider the possibility that such acyl phosphonates could be deoxygenated through a 
Wolff-Kishner-type reduction to give alkyl phosphonates.  Such a reaction would allow 
alkyl phosphonates to be readily accessed from carboxylic acid precursors (Scheme 5.2). 
At first glance such a proposal may seem unattractive, given that Wolff-Kishner 
conditions are quite harsh (the frequently-used Huang-Minlon modification calls for 
ethylene glycol and potassium hydroxide at 200 ºC).16,17 However, we reasoned that the 
electron-withdrawing phosphonate group could stabilize the carbanionic character of the 
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Scheme 5.2. Retrosynthesis of phosphonates from carboxylic acids
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presumed key intermediate (Scheme 
5.3). The related transition state 
stabilization would allow this reaction 
variant to be much milder. 
 To test this proposal, we synthesized the hydrazone of diethyl 
propionylphosphonate.  Guided by several reports of low temperature (≤ 100 ºC) Wolff-
Kishner reductions,18 we slowly added the hydrazone to a rapidly stirring mixture of ten 
equivalents potassium tert-butoxide in dimethyl sulfoxide at room temperature. 
Pleasingly, a trace amount of diethyl propylphosphonate could be detected in the crude 
reaction mixture by 31P NMR. After exploring a variety of reaction conditions with the 
screening robot in the Caltech Center for Catalysis and Chemical Synthesis, we found 
that good (≥ 70%) yields of diethyl propylphosphonate could be obtained at room 
temperature using potassium tert-butoxide in a 50% v/v tetrahydrofuran:tert-butanol 
solvent mixture. 
 We then turned our attention toward the hydrazone-formation step, seeking 
conditions that would allow the crude hydrazone to be used directly in the base-promoted 
reduction step. Using 
propionyl phosphonate 
as the model substrate, 
we found that 
moderately acidic 
conditions worked best: 
strongly acidic 
R P
O
OEt
OEt
NHN
R P
O
OEt
OEt
NHN
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O
OEt
OEt
NHN
Scheme 5.3. Electron-withdrawing phosphonate 
stabilizes the key intermediate
R P
O
OEt
OEt
O
R N
H
O
NH2
R P
O
OEt
OEt
NH2N
no additive
H2N NH2
mild 
acid
strong acidNO 
REACTION
Scheme 5.4. Hydrazone formation is pH-dependent.
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conditions led to no reaction, while pH-neutral and basic conditions led to decomposition 
of the starting material into propionyl hydrazide and diethylphosphite (Scheme 5.4). 
These observations are consistent with the trends observed in the formation of Schiff 
bases and related structures,19 except—in this case—higher pHs lead to decomposition 
rather than merely slower rates. The observed decomposition products are consistent with 
elimination of the phosphite from the presumed tetrahedral intermediate, indicating that 
the elimination of phosphite is favored under basic or neutral conditions, while the 
elimination of water is favored under acidic conditions. 
 We next sought to combine the hydrazone-formation and reduction steps.  Since 
hydrazone formation is a reversible process, we anticipated that the direct addition of 
base to the water-containing hydrazone-formation reaction would lead to the same 
decomposition products observed previously (dialkylphosphite and propionyl hydrazide). 
This prediction was confirmed in practice under a variety of conditions. Similarly, when 
one equivalent of water was added to the reduction reaction of the purified hydrazone, the 
yield was dramatically reduced. Therefore, water must be removed from the hydrazone-
forming reaction prior to its treatment with base. Adding desiccants to the reaction 
mixture (e.g., MgSO4, molecular sieves, etc.) gave low and inconsistent yields of the 
propyl phosphonate, even when the desiccant was filtered off prior to base addition. 
Evaporation of the liquid reactions under hi-vacuum failed to remove all the water, and 
the resultant oils gave poor yields of phosphonate when the reduction conditions were 
applied. However, when benzene was used as solvent in combination with a solid acid 
additive such as benzoic acid, the reaction mixture could be flash-frozen and placed 
under hi-vacuum to effectively remove all water, leaving behind a powdery solid matrix 
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of hydrazone and benzoic acid. Applying the reduction conditions to the residual 
lyophilized powder gave the phosphonate in consistently satisfactory yields. 
 Having arrived at a two-step, one-pot deoxygenation of propionyl phosphonate, 
we set out to explore the substrate scope of this transformation, only to realize that the 
starting acyl phosphonates could be purified only by distillation (in our hands, these 
compounds would not crystallize as solids, and they decomposed during 
chromatography). Fortunately, the “acyl-Arbuzov” reaction is quite clean, and the crude 
product can be used directly after the in vacuo removal of the volatile chloroethane, 
eliminating any possible side reactions involving this byproduct. This led us to a one-pot, 
three-step (or four-step, in cases where the acid chloride is formed in situ) sequence for 
the direct conversion of acid chlorides/carboxylic acids to diethyl phosphonates. The 
optimized sequence is as follows. First, the acid is treated with oxalyl chloride and 
catalytic dimethylformamide in dichloromethane. After removal of solvent and excess 
reagent in vacuo, the acid chloride is redissolved in dichlormethane and treated with one 
equivalent of triethylphosphite at 0 ºC. Solvent and byproduct are again removed in 
vacuo; then, benzene and two molar equivalents benzoic acid are added to the residue. 
Dropwise addition of a slight molar excess of commercially available 1.0 M hydrazine in 
THF solution yields the hydrazone in several minutes. This solution is then lyophilized to 
give a finely dispersed solid mixture of benzoic acid and the hydrazone. The solid is then 
dissolved in 50% v/v tetrahydrofuran:tert-butanol and treated with three equivalents of 
0.6 M potassium tert-butoxide in 50% v/v tetrahydrofuran:tert-butanol at room 
temperature. Solid potassium benzoate immediately precipitates, and typical reactions 
turn yellow in color; gas evolution can be observed immediately. The reaction is then 
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quenched with water, washed with saturated sodium bicarbonate, and purified by flash 
column chromatography to yield the pure phosphonate. 
 This reaction works well for simple carboxylic acids, yielding ≥ 58% for the 
sequence, corresponding to nearly 90% per step (Table 5.1). However, yields fall 
significantly for alpha-branched substrates (entries 3-5). NMR analysis of the reaction of 
isobutyryl chloride indicated that the acyl phosphonate is formed in high yield, but much 
of it decomposed to diethylphosphite and isobutyryl hydrazide during the hydrazone 
formation step.  These are the same side products that we observed when trying to form 
the hydrazone of propionyl phosphonate under basic conditions (Scheme 5.4). Given that 
alpha branching leads to a more sterically crowded tetrahedral intermediate, we postulate 
that this steric crowding increases the effective nucleofugality of the bulky phosphite 
substituent relative to water. Having previously established that acid biases the 
O
Cl P(O)(OEt)2
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Cl P(O)(OEt)2
O
Cl P(O)(OEt)2
O
Cl P(O)(OEt)2
O
Cl P(O)(OEt)2
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Cl P(O)(OEt)2
1
2
3a
4
5a
6
58 (83)
74 (90)
35 (70)
65 (87)
< 5
21 (59)
Table 5.1. Acyl Arbuzov-reductive deoxygenation reactions
R
O
Cl/OH P(O)(OEt)2R
1) 1.2 equiv (COCl)2a
2) 1.0 equiv P(OEt)3
3) 1.05 equiv N2H4, 2.0 equiv BzOH
4) 3.0 equiv KOtBu
entry substrate product yield (%)b
45 (77)3bc
5bd 30 (67)
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7
8
9
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74 (90)
69 (91)
65 (90)
58 (87)
< 5
< 5
entry substrate product yield (%)b
(a) oxalyl chloride used where necessary; (b) number in parentheses represents per-step yield; (c) four equiv 
benzoic acid used in hydrazone formation; (d) two equiv o-bromobenzoic acid used.
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tetrahedral intermediate towards the elimination of water over phosphite, we performed 
the same reaction using slightly more acidic conditions. Consistent with our hypotheses, 
this adjustment led to a small improvement in yield but a much slower reaction (entry 
3b). Benzoyl chloride also gave poor yields (entry 5).  Alpha branching may contribute to 
the low yield, but there are likely some electronic factors also in play, as benzoyl 
phosphonate is much less reactive than other acyl phosphonates under the hydrazone-
forming reaction conditions (reaction times are 100-1000-fold longer). 
 Functional groups such as ethers (entry 9) and nitriles (entry 10) are well tolerated 
by the reaction, while amides (entry 11) and esters (entry 12) give poor yields, 
presumably due to the reaction of the carboxyl group with the hydrazine.  While there are 
thus some limitations to the scope of this reaction sequence, it compares favorably to the 
conventional Arbuzov reaction in many cases. 
 In conclusion, we have developed a one-pot protocol for the Wolff-Kishner type 
reductive deoxygenation of acyl phosphonates. We have further adapted this reaction to 
develop a one-pot sequence for the synthesis of alkyl phosphonates from carboxylic 
acids. We anticipate that this new reaction will offer a low-temperature alternative to the 
Arbuzov reaction for the synthesis of this important class of compounds. 
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Chemistry—General 
 
All reactions were performed under argon using solvents that were dried and purified 
according to the method of Grubbs.20 All flasks and vials were oven dried at 122 °C and 
cooled in a desiccator box containing anhydrous calcium sulfate. But for the exceptions 
listed here, commercial reagents were purified according to the methods compiled by 
Armengo and Perrin.21 Potassium t-butoxide, anhydrous t-butanol, and 1.0 M hydrazine 
in THF solution were used as purchased from Aldrich without further purification and 
stored under argon. Hydrocinnamic acids that could not be purchased were synthesized 
from the corresponding benzaldehyde according to a literature procedure.22 Reactions 
were monitored by thin-layer chromatography on Merck Siligel 60-F254. Compounds 
were visualized with a UV lamp (254 nm) and stained with potassium permanganate 
solution.  Column chromatography was carried out in accordance with the methods of 
Still23 using EMD-Merck silica gel 60, 230-400 mesh ASTM. 1H, 31P, and 13C NMR 
spectra were acquired on a Varian Mercury 300 MHz spectrometer. High-resolution mass 
spectrometry was performed on a JEOL JMS-600H HRMS using an Electrospray Ion 
Source. NMR spectra for the compounds synthesized here can be found in the supporting 
information of the original publication.1 
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Chemistry—Synthesis 
 
Diethyl ethylphosphonate (Table 5.1, entry 1). Acetyl chloride (72 µL, 1 mmol) was 
added to dichloromethane (8 mL) in a 25 mL round-bottomed flask and cooled on an 
icebath. Triethylphosphite (171 µL, 1 mmol) was then added dropwise to this chilled 
solution under stirring, then the reaction was allowed to come to room temperature. After 
two hours stirring, the reaction was reduced in vacuo, and benzoic acid (245 mg, 2 mmol) 
was added directly to the residue, followed by benzene (10 mL). The mixture was stirred 
to dissolve completely, then hydrazine solution (1.05 mL, 1.0 M in THF, 1.05 mmol) was 
added dropwise under rapid stirring. After 90 minutes, the reaction was flash-frozen and 
lyophilized. After lyophilization, 1:1 v/v tetrahydrofuran:tert-butanol (10 mL) was added 
to the flask and stirred to dissolve the solid. Potassium tert-butoxide solution (5 mL, 0.6 
M in 1:1 v/v tetrahydrofuran:tert-butanol, 3 mmol) was then added to the stirring solution 
in one portion. After 6 h room temperature stirring, the reaction was diluted with ethyl 
acetate (50 mL), quenched with 1 N HCl (20 mL), washed with saturated sodium 
bicarbonate (2 x 15 mL), then with brine (15 mL), dried on sodium sulfate, reduced in 
vacuo, then purified by flash chromatography on silica (15% acetone in dichloromethane) 
to give the desired product as a colorless liquid; 97.0 mg (58.4%). 1H NMR (300 MHz, 
CDCl3) δ 3.98-4.12 (m, 4H), 1.62-1.68, (dq, 2H, J = 18.2, 7.8 Hz), 1.28 (t, 3H, J = 7.1 
Hz), 1.11 (dt, 6H, J = 20.0, 7.8 Hz); 13C NMR (75 MHz, CDCl3) δ 61.4, 61.3, 19.7, 17.8, 
16.4, 16.5, 6.5, 6.4; 31P NMR (121 MHz, CDCl3) δ 33.6; HRMS (FAB+) calculated for 
[C6H16O3P] ([M+H]+) 167.0837, found 167.0836.24 
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Diethyl propylphosphonate. (Table 5.1, entry 2). Propionyl chloride (87 µL, 1 mmol) 
was added to dichloromethane (8 mL) in a 25 mL round-bottomed flask and cooled on an 
icebath. Triethylphosphite (171 µL, 1 mmol) was then added dropwise to this chilled 
solution under stirring, then the reaction was allowed to come to room temperature. After 
one hour stirring, the reaction was reduced in vacuo, and benzoic acid (245 mg, 2 mmol) 
was added directly to the residue, followed by benzene (10 mL). The mixture was stirred 
to dissolve completely, then hydrazine solution (1.05 mL, 1.0 M in THF, 1.05 mmol) was 
added dropwise under rapid stirring. After 60 minutes, the reaction was flash-frozen and 
lyophilized. After lyophilization, 1:1 v/v tetrahydrofuran:tert-butanol (10 mL) was added 
to the flask and stirred to dissolve the solid. Potassium tert-butoxide solution (5 mL, 0.6 
M in 1:1 v/v tetrahydrofuran:tert-butanol, 3 mmol) was then added to the stirring solution 
in one portion. After 6 h room temperature stirring, the reaction was diluted with ethyl 
acetate (50 mL), quenched with 1 N HCl (20 mL), washed with saturated sodium 
bicarbonate (2 x 15 mL), then with brine (15 mL), dried on sodium sulfate, reduced in 
vacuo, then purified by flash chromatography on silica (10% acetone in dichloromethane) 
to give the desired product as a colorless liquid; 133.8 mg (74.3 %). 1H NMR (300 MHz, 
CDCl3) δ 3.93-4.11 (m, 4H), 1.48-1.70, (m, 4H), 1.25 (t, 6H, J = 7.1 Hz), 0.92-0.97 (m, 
3H); 13C NMR (75 MHz, CDCl3) δ 61.3, 61.2, 28.6, 26.7, 16.4, 16.3, 16.1, 16.0, 15.3, 
15.1; 31P NMR (121 MHz, CDCl3) δ 32.2; HRMS (FAB+) calculated for [C7H18O3P] 
([M+H]+) 181.0994, found 181.1003.25 
 
Diethyl sec-butylphosphonate. (Table 5.1, entry 3b). 2-Methylpropionyl chloride (106 
mg, 1 mmol) was added to dichloromethane (8 mL) in a 25 mL round-bottomed flask and 
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cooled on an icebath. Triethylphosphite (171 µL, 1 mmol) was then added dropwise to 
this chilled solution under stirring, then the reaction was allowed to come to room 
temperature. After one hour stirring, the reaction was reduced in vacuo, and benzoic acid 
(500 mg, 4 mmol) was added directly to the residue, followed by benzene (10 mL). The 
mixture was stirred to dissolve completely, then hydrazine solution (1.05 mL, 1.0 M in 
THF, 1.05 mmol) was added dropwise under rapid stirring. After 60 minutes, the reaction 
was flash-frozen and lyophilized. After lyophilization, 1:1 v/v tetrahydrofuran:tert-
butanol (7 mL) was added to the flask and stirred to dissolve the solid. Potassium tert-
butoxide solution (8 mL, 0.6 M in 1:1 v/v tetrahydrofuran:tert-butanol, 5 mmol) was then 
added to the stirring solution in one portion. After 12 h room temperature stirring, the 
reaction was diluted with ethyl acetate (50 mL), quenched with 1 N HCl (20 mL), washed 
with saturated sodium bicarbonate (2 x 15 mL), then with brine (15 mL), dried on sodium 
sulfate, reduced in vacuo, then purified by flash chromatography on silica (12% acetone 
in dichloromethane) to give the desired product as a colorless liquid; 88.5 mg (45.6 %). 
1H NMR (300 MHz, CDCl3) δ 3.96-4.14 (m, 4H), 1.95-2.12 (m, 1H), 1.63 (dd, 2H, J = 
18.2, 6.8 Hz), 1.28 (t, 6H, J = 7.1 Hz), 1.01 (dd, 6H J = 6.7, 1.0 Hz); 13C NMR (75 MHz, 
CDCl3) δ 61.2, 61.1, 35.4, 33.6, 24.1, 24.0, 23.7, 23.7, 16.5, 16.4; 31P NMR (121 MHz, 
CDCl3) δ 31.6; HRMS (FAB+) calculated for [C8H20O3P] ([M+H]+) 195.1150, found 
195.1173.26 
 
Diethyl benzylphosphonate. (Table 5.1, entry 5b). Benzoyl chloride (117 µL, 1 mmol) 
was added to dichloromethane (8 mL) in a 25 mL round-bottomed flask and cooled on an 
icebath. Triethylphosphite (171 µL, 1 mmol) was then added dropwise to this chilled 
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solution under stirring, then the reaction was allowed to come to room temperature. After 
one hour stirring, the reaction was reduced in vacuo, and ortho-bromobenzoic acid (400 
mg, 2 mmol) was added directly to the residue, followed by benzene (10 mL). The 
mixture was stirred, then hydrazine solution (1.05 mL, 1.0 M in THF, 1.05 mmol) was 
added dropwise under rapid stirring. After 6 hours, the reaction was flash-frozen and 
lyophilized. After lyophilization, 1:1 v/v tetrahydrofuran:tert-butanol (10 mL) was added 
to the flask and stirred to dissolve the solid. Potassium tert-butoxide solution (5 mL, 0.6 
M in 1:1 v/v tetrahydrofuran:tert-butanol, 3 mmol) was then added to the stirring solution 
in one portion. After 4 h room temperature stirring, the reaction was diluted with ethyl 
acetate (50 mL), quenched with 1 N HCl (20 mL), washed with saturated sodium 
bicarbonate (2 x 15 mL), then with brine (15 mL), dried on sodium sulfate, reduced in 
vacuo, then purified by flash chromatography on silica (15% acetone in dichloromethane) 
to give the desired product as a colorless liquid; 68.6 mg (30.1 %). 1H NMR (300 MHz, 
CDCl3) δ 7.23-7.31 (m, 5H), 3.95-4.06 (m, 4H), 3.15 (d, 2H, J = 21.6 Hz), 1.24 (t, 6H, J 
= 7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 131.6, 131.6, 129.8, 129.7, 128.5, 128.5, 126.9, 
126.8, 62.1, 62.1, 34.3, 33.2, 16.4, 16.3; 31P NMR (121 MHz, CDCl3) δ 26.4; HRMS 
(FAB+) calculated for [C11H18O3P] ([M+H]+) 229.0994, found 229.1005.27 
 
Diethyl 2-phenylethylphosphonate. (Table 5.1, entry 6). Phenylacetyl chloride (154 
mg, 1 mmol) was added to dichloromethane (8 mL) in a 25 mL round-bottomed flask and 
cooled on an icebath. Triethylphosphite (171 µL, 1 mmol) was then added dropwise to 
this chilled solution under stirring, then the reaction was allowed to come to room 
temperature. After two hours stirring, the reaction was reduced in vacuo, and benzoic 
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acid (245 mg, 2 mmol) was added directly to the residue, followed by benzene (10 mL). 
The mixture was stirred to dissolve completely, then hydrazine solution (1.05 mL, 1.0 M 
in THF, 1.05 mmol) was added dropwise under rapid stirring. After 60 minutes, the 
reaction was flash-frozen and lyophilized. After lyophilization, 1:1 v/v 
tetrahydrofuran:tert-butanol (10 mL) was added to the flask and stirred to dissolve the 
solid. Potassium tert-butoxide solution (5 mL, 0.6 M in 1:1 v/v tetrahydrofuran:tert-
butanol, 3 mmol) was then added to the stirring solution in one portion. After 6 h room 
temperature stirring, the reaction was diluted with ethyl acetate (50 mL), quenched with 1 
N HCl (20 mL), washed with saturated sodium bicarbonate (2 x 15 mL), then with brine 
(15 mL), dried on sodium sulfate, reduced in vacuo, then purified by flash 
chromatography on silica (15% acetone in dichloromethane) to give the desired product 
as a yellow liquid; 158.1 mg (65.3 %). 1H NMR (300 MHz, CDCl3) δ 7.16-7.30 (m, 5H), 
4.03-4.13 (m, 4H), 2.85-2.94 (m, 2H), 1.98-2.10 (m, 2H), 1.30 (t, 6H J = 7.0 Hz); 13C 
NMR (75 MHz, CDCl3) δ 141.1, 140.8, 128.5, 128.0, 126.3, 61.6, 61.5, 28.6, 28.5, 28.5, 
26.6, 16.5, 16.4; 31P NMR (121 MHz, CDCl3) δ 30.8; HRMS (FAB+) calculated for 
[C12H20O3P] ([M+H]+) 243.1150, found 243.1158.27 
 
Diethyl 3-phenylpropyl-1-phosphonate. (Table 5.1, entry 7). 3-Phenylpropionyl 
chloride (149 µL, 1 mmol) was added to dichloromethane (8 mL) in a 25 mL round-
bottomed flask and cooled on an icebath. Triethylphosphite (171 µL, 1 mmol) was then 
added dropwise to this chilled solution under stirring, then the reaction was allowed to 
come to room temperature. After two hours stirring, the reaction was reduced in vacuo, 
and benzoic acid (245 mg, 2 mmol) was added directly to the residue, followed by 
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benzene (10 mL). The mixture was stirred to dissolve completely, then hydrazine solution 
(1.05 mL, 1.0 M in THF, 1.05 mmol) was added dropwise under rapid stirring. After 90 
minutes, the reaction was flash-frozen and lyophilized. After lyophilization, 1:1 v/v 
tetrahydrofuran:tert-butanol (10 mL) was added to the flask and stirred to dissolve the 
solid. Potassium tert-butoxide solution (5 mL, 0.6 M in 1:1 v/v tetrahydrofuran:tert-
butanol, 3 mmol) was then added to the stirring solution in one portion. After 6 h room 
temperature stirring, the reaction was diluted with ethyl acetate (50 mL), quenched with 1 
N HCl (20 mL), washed with saturated sodium bicarbonate (2 x 15 mL), then with brine 
(15 mL), dried on sodium sulfate, reduced in vacuo, then purified by flash 
chromatography on silica (100% ethyl acetate) to give the desired product as a faintly 
yellow liquid; 189.0 mg (73.8 %). 1H NMR (300 MHz, CDCl3) δ 7.12-7.28 (m, 5H), 
3.95-4.12 (m, 4H), 2.64-2.69 (t, 2H, J = 7.4 Hz), 1.84-1.97 (m, 2H), 1.64-1.75 (m, 2H), 
1.27 (t, 6H J = 7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 141.0, 141.0, 128.4, 128.3, 126.0, 
61.4, 61.3, 36.5, 36.3, 26.0, 24.2, 24.1, 24.1, 16.5, 16.4; 31P NMR (121 MHz, CDCl3) δ 
32.0; HRMS (FAB+) calculated for [C13H22O3P] ([M+H]+) 257.1307, found 257.1302.27 
 
Diethyl 3-phenylpropyl-1-phosphonate. (Table 5.1, entry 8). 3-Phenylpropionic acid 
(150 mg, 1 mmol) was dissolved in dichloromethane (10 mL) in a 25 mL round-bottomed 
flask and cooled on an icebath. Oxalyl chloride (100 µL, 1.2 mmol) was added in one 
portion under stirring, and the reaction was allowed to come to room temperature. After 
12 hours the reaction was reduced in vacuo, then the residue was redissolved in 
dichloromethane (8 mL) and cooled on an icebath. Triethylphosphite (171 µL, 1 mmol) 
was then added dropwise to this chilled solution under stirring, then the reaction was 
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allowed to come to room temperature. After two hours stirring, the reaction was reduced 
in vacuo, and benzoic acid (245 mg, 2 mmol) was added directly to the residue, followed 
by benzene (10 mL). The mixture was stirred to dissolve completely, then hydrazine 
solution (1.05 mL, 1.0 M in THF, 1.05 mmol) was added dropwise under rapid stirring. 
After 90 minutes, the reaction was flash-frozen and lyophilized. After lyophilization, 1:1 
v/v tetrahydrofuran:tert-butanol (10 mL) was added to the flask and stirred to dissolve the 
solid. Potassium tert-butoxide solution (5 mL, 0.6 M in 1:1 v/v tetrahydrofuran:tert-
butanol, 3 mmol) was then added to the stirring solution in one portion. After 6 h room 
temperature stirring, the reaction was diluted with ethyl acetate (50 mL), quenched with 1 
N HCl (20 mL), washed with saturated sodium bicarbonate (2 x 15 mL), then with brine 
(15 mL), dried on sodium sulfate, reduced in vacuo, then purified by flash 
chromatography on silica (100% ethyl acetate) to give the desired product as a faintly 
yellow liquid; 177.0 mg (69.1 %). 1H NMR (300 MHz, CDCl3) δ 7.15-7.30 (m, 5H), 
3.97-4.15 (m, 4H), 2.66-2.71 (t, 2H, J = 7.4 Hz), 1.84-1.99 (m, 2H), 1.66-1.78 (m, 2H), 
1.29 (t, 6H J = 7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 141.0, 141.0, 128.5, 128.4, 126.0, 
61.4, 61.3, 36.5, 36.3, 26.0, 24.2, 24.1, 16.5, 16.4; 31P NMR (121 MHz, CDCl3) δ 32.0; 
HRMS (FAB+) calculated for [C13H22O3P] ([M+H]+) 257.1307, found 257.1302. 
 
Diethyl 3-(4-methoxyphenyl)propyl-1-phosphonate. (Table 5.1, entry 9). 3-(4-
methoxyphenyl) propionic acid (180 mg, 1 mmol) was dissolved in dichloromethane (10 
mL) in a 25 mL round-bottomed flask and cooled on an icebath. Oxalyl chloride (100 µL, 
1.2 mmol) was added in one portion under stirring, and the reaction was allowed to come 
to room temperature. After 12 hours the reaction was reduced in vacuo, then the residue 
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was redissolved in dichloromethane (8 mL) and cooled on an icebath. Triethylphosphite 
(171 µL, 1 mmol) was then added dropwise to this chilled solution under stirring, then 
the reaction was allowed to come to room temperature. After two hours stirring, the 
reaction was reduced in vacuo, and benzoic acid (245 mg, 2 mmol) was added directly to 
the residue, followed by benzene (10 mL). The mixture was stirred to dissolve 
completely, then hydrazine solution (1.05 mL, 1.0 M in THF, 1.05 mmol) was added 
dropwise under rapid stirring. After 90 minutes, the reaction was flash-frozen and 
lyophilized. After lyophilization, 1:1 v/v tetrahydrofuran:tert-butanol (10 mL) was added 
to the flask and stirred to dissolve the solid. Potassium tert-butoxide solution (5 mL, 0.6 
M in 1:1 v/v tetrahydrofuran:tert-butanol, 3 mmol) was then added to the stirring solution 
in one portion. After 6 h room temperature stirring, the reaction was diluted with ethyl 
acetate (50 mL), quenched with 1 N HCl (20 mL), washed with saturated sodium 
bicarbonate (2 x 15 mL), then with brine (15 mL), dried on sodium sulfate, reduced in 
vacuo, then purified by flash chromatography on silica (100% ethyl acetate) to give the 
desired product as a faintly yellow liquid; 187.4 mg (65.5 %). 1H NMR (300 MHz, 
CDCl3) δ 7.03-7.06 (m, 2H), 6.77-6.80 (m 2H), 3.94-4.12 (m, 4H), 3.74 (s, 3H), 2.60 (t, 
2H, J = 7.4 Hz), 1.79-1.93 (m, 2H), 1.62-1.75 (m, 2H), 1.27 (t, 6H J = 7.1 Hz); 13C NMR 
(75 MHz, CDCl3) δ 157.9, 133.1, 133.0, 129.3, 113.8, 61.4, 61.3, 55.2, 35.6, 35.4, 25.9, 
24.3, 24.3, 24.0, 16.5, 16.4; 31P NMR (121 MHz, CDCl3) δ 32.2; HRMS (FAB+) 
calculated for [C14H23O4P] ([M+H]+) 286.1334, found 286.1342. 
 
Diethyl 3-(4-cyanophenyl)propyl-1-phosphonate. (Table 5.1, entry 10). 3-(4-
cyanophenyl) propionic acid (175 mg, 1 mmol) was dissolved in dichloromethane (10 
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mL) in a 25 mL round-bottomed flask and cooled on an icebath. A drop of 
dimethylformamide was added. Oxalyl chloride (100 µL, 1.2 mmol) was added in one 
portion under stirring, and the reaction was allowed to come to room temperature. After 
12 hours the reaction was reduced in vacuo, then the residue was redissolved in 
dichloromethane (8 mL) and cooled on an icebath. Triethylphosphite (171 µL, 1 mmol) 
was then added dropwise to this chilled solution under stirring, then the reaction was 
allowed to come to room temperature. After two hours stirring, the reaction was reduced 
in vacuo, and benzoic acid (245 mg, 2 mmol) was added directly to the residue, followed 
by benzene (10 mL). The mixture was stirred to dissolve completely, then hydrazine 
solution (1.05 mL, 1.0 M in THF, 1.05 mmol) was added dropwise under rapid stirring. 
After 90 minutes, the reaction was flash-frozen and lyophilized. After lyophilization, 1:1 
v/v tetrahydrofuran:tert-butanol (10 mL) was added to the flask and stirred. Potassium 
tert-butoxide solution (5 mL, 0.6 M in 1:1 v/v tetrahydrofuran:tert-butanol, 3 mmol) was 
then added to the stirring mixture in one portion. After 6 h room temperature stirring, the 
reaction was diluted with ethyl acetate (50 mL), quenched with 1 N HCl (20 mL), washed 
with saturated sodium bicarbonate (2 x 15 mL), then with brine (15 mL), dried on sodium 
sulfate, reduced in vacuo, then purified by flash chromatography on silica (20% acetone 
in dichloromethane) to give the desired product as a colorless liquid; 163.5 mg (58.2 %). 
1H NMR (300 MHz, CDCl3) δ 7.51-7.55 (m, 2H), 7.23-7.27 (m 2H), 3.96-4.13 (m, 4H), 
2.73 (t, 2H, J = 7.5 Hz), 1.83-1.97 (m, 2H), 1.63-1.74 (m, 2H), 1.27 (t, 6H J = 7.1 Hz); 
13C NMR (75 MHz, CDCl3) δ 146.7, 132.2, 129.3, 118.9, 110.0, 61.6, 61.5, 36.5, 36.3, 
25.9, 24.0, 23.8, 23.7, 16.5, 16.4; 31P NMR (121 MHz, CDCl3) δ 31.3; HRMS (FAB+) 
calculated for [C14H21O3NP] ([M+H]+) 282.1259, found 282.1262. 
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Section 2: Chapter 6 
 
 
 
The Reductive Coupling of Aldehydes/Ketones with Dialkyl Phosphites: 
A Mild and Orthogonal Alternative to the Arbuzov Reaction 
 
 
Abstract: A new method for the synthesis of phosphonates through the reductive 
coupling of aldehydes/ketones and dialkyl phosphites is described. The reaction proceeds 
through a mesitylenesulfonyl hydrazone intermediate and shows broad substrate scope 
and functional group tolerance. The method tolerates azides and benzyl halides, making 
it complementary to the Arbuzov reaction. The new method does not work for aliphatic 
aldehydes, but progress towards modifying the methodology to work for these substrates 
is presented. 
 
 Chapter 5 presented a novel method for the conversion of carboxylic acids to 
phosphonates in a single pot, first by generating the acyl phosphonate through an 
Arbuzov-type mechanism, then by deoxygenating that intermediate using a Wolff-
Kishner-type mechanism.1 This route is mechanistically novel, but the use of strong acids 
and bases limits the functional group compatibility of the method, and the multiple 
rounds of reagent addition and solvent exchange diminish its attractiveness from a 
practical perspective. For these reasons it falls short of our goal of a methodology for 
phosphonate formation that is milder than and orthogonal to the conventional Arbuzov 
reaction.2 
 The acyl phosphonate deoxygenation method is presumed to proceed through 
diazene intermediate 1, which rapidly decomposes into nitrogen gas and the desired 
product (Scheme 6.1). In the deoxygenation method, this intermediate is formed by the 
terminal deprotonation of hydrazone 2; we rationalized that this intermediate may also be 
accessible through the nucleophilic addition of a dialkyl phosphite 4 into tosylhydrazone 
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3. If so, then a method could be envisioned in which aldehydes or ketones could be 
directly converted into phosphonates via combination with tosylhydrazide and a dialkyl 
phosphite. 
 The literature contains 
strong precedent for such a 
reductive coupling strategy. The 
Myers lab has developed a 
multistep strategy using a silyl-
protected tosylhydrazone intermediate for the reductive coupling of aldehydes and 
organolithium compounds.3 Organic cyanides4 and tert-butyl ethers5 can also be accessed 
in a single operational step using this strategy. Bertz and Dabbaugh demonstrated the 
application of this strategy using phosphine oxides in a two-step process.6 Inokawa, et al. 
reported the route envisioned here: the reductive coupling of ketones with 
dialkylphosphites to give phosphonates using tosylhydrazone (Scheme 6.2).7 However, 
Inokawa’s reported methodology suffers several key drawbacks. First, it uses three steps, 
requiring the isolation and purification of the hydrazone intermediate 3 and the 
hydrazone-phosphite tetrahedral adduct 5. Second, the overall sequence takes at least a 
week. Third, the authors only present five substrates, and none contain any functionality 
other than the ketone that is undergoing reaction. 
R P
O
OEt
OEt
NHN
R HP
O
OEt
OEt
NXHN
R P
O
OEt
OEt
NH2N
312 4
Scheme 6.1. The key diazene 1 that presumably leads 
to product phosphonate could arise in multiple ways.
R R'
O
R R'
NTsHN
R
NHTsHN
P
O
OEt
OEt
5
R' R PO
OEt
OEt
R'
HP(O)(OMe)2
7 days, rt
NaBH4, 2h
THF, reflux
3
Scheme 6.2. Phosphonates from ketones according to the method of Inokawa.
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 Using acetone as a model substrate, we set out to develop a single-step protocol. 
Heating acetone, tosylhydrazide, and dimethylphosphite in a sealed vial at 85 °C for 12 
hours in acetonitrile resulted in only trace product 7 (Table 6.1). Since addition of the 
phosphite into the hydrazone was the slowest step in the Inokawa protocol, we reasoned 
that the addition of a Lewis acid might accelarate this step by coordinating to the 
hydrazone and activating the electrophilic carbon toward attack from the phosphite. Upon 
screening, many Lewis acids offered improvement, but the best three were the trivalent 
trifluoromethanesulfonate salts of yttrium, scandium, and indium. These Lewis acids are 
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regarded as amongst the most azaphilic, lending support to the hypothesis that they 
function by coordinating to the hydrazone 3 to promote addition of the phosphite to form 
the tetrahedral adduct 5.8 
  Other sulfonyl hydrazides were also screened. Mesitylenesulfonyl hydrazide 
consistently gave the best results of the commercially available sulfonyl hydrazides. The 
literature suggests that the bulkier mesitylene sufinate is more reactive than the toluene 
sufinate in the decomposition of the corresponding hydrazides and hydrazones.9 The 
bulkier 2,4,6-triisopropylbenzenesulfonyl hydrazide is known to be even more reactive in 
this regard, but its poor solubility under the reaction conditions may have led to the 
poorer results observed when it was screened. o-Nitrobenzenesulfonyl hydrazide led to 
much poorer results despite the reactivity trend; perhaps direct decomposition of this 
hydrazide under the reaction conditions becomes an issue. 
 Solvent, temperature, concentration, and stoichiometry were also screened. 
Noncoordinating solvents such as chloroform and toluene were shown to perform better 
than polar, coordinating solvents such as acetonitrile, dimethylsulfoxide, and 
tetrahydrofuran, perhaps because these solvents coordinate and sequester the Lewis acid 
catalyst. 60 °C was typically sufficient for the reactions to run to completion in 48 hours 
or less, while direct decomposition of the hydrazide became an issue at higher 
temperatures. For acetone and other ketone substrates, 1-2 mol% Lewis acid was 
typically sufficient, while benzaldehyde substrates benefitted from higher catalyst 
loadings: 10 mol% was typically sufficient. Pleasingly, superstoichiometric amounts of 
hydrazide relative to the aldehyde/ketone substrate provided little benefit to the yield, 
giving no need to add extra hydrazide, which could react with other functional groups in 
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a more complicated substrate. In contrast, optimized conditions require a one-equivalent 
excess of dialkyl phosphite, which fortunately (with respect to side reactions) is a much 
weaker nucleophile than mesitylenesulfonyl hydrazide. The excess phosphite—while 
often difficult to chromatographically separate from the product phosphonate—can be 
easily removed under high vacuum (in the case of dimethyl or diethyl phosphite). If the 
product phosphonate is also volatile, the phosphite can be selectively oxidized in the 
presence of the product phosphonate by treatment of the crude reaction product with 
Table 6.2. Reaction scope.
entry substrate product yield (%)
Y(OTf)3 (0.1 equiv)
MesSNHNH2 (1 equiv)
CHO P(O)(OEt)2
MeO
MeO
MeO
MeO
CHO P(O)(OEt)2
N3 N3
CHO P(O)(OEt)2
N3 N3
CHO P(O)(OEt)2
CHO P(O)(OEt)2
F F
CHO P(O)(OEt)2
Cl Cl
59
Br Br
71
60
66
60
89
CHO P(O)(OEt)2
R R
HP(O)(OEt)2 (2 equiv)
CHCl3 (0.1 M), 60 °C
3
4
2
5
6
1
8 9
8c
8d
8b
8f
8a
8e
9c
9d
9b
9f
9a
9e
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iodine in a water-methanol mixture at room temperature. The resulting phosphate diester 
monoanion can then be easily removed by extraction or chromatography. These 
optimized conditions yielded the desired phosphonate in yields > 95% by GC for the 
acetone test substrate. 
 In exploring the substrate scope, the reaction conditions proved to be tolerant of a 
wide range of functional groups (Table 6.2). Ethers (entry 1), amides, esters, cyanides, 
nitro compounds, benzyl chlorides (entry 4), benzyl bromides (entry 6), and azides 
(entries 2 & 3) all worked. In the case of benzaldehyde substrates, electron-rich substrates 
generally reacted faster and gave better yields than electron-poor substrates, but yields in 
excess of 50% could still be obtained for these substrates. The fact that nitro groups, 
azides, and benzyl halides are untouched by these reaction conditions is particularly 
exciting, because phosphonates containing these functional groups are not accessible 
through the Arbuzov reaction, illustrating the orthogonality of this new process (nitro 
compounds are reduced by trialkyl phosphites at high temperatures, though Arbuzov 
reactions can usually be run at a time/temperature where this is only a minor side-
reaction).10,11 
 Anilines and pyridines, which are incompatible with Arbuzov conditions due to 
their nucleophilic nitrogen, give poor yields under these conditions also (Table 6.3). 
When reactions using 4-dimethylaminobenzaldehyde and 4-formylpyridine were 
monitored by NMR, it was noted that the majority of the mass balance of the aldehyde 
substrate existed as the aldehyde, even after several hours of reaction. In contrast, only 
hydrazone was visible by 1H NMR for other aldehyde substrates, even when the spectrum 
was taken just minutes after combining the reactants. To explore this further, one 
  
90 
equivalent of pyridine was added to the reaction of 3,4-dimethoxybenzaldehyde (8a). 
Extremely poor yields were obtained, and 1H NMR showed a lot of unreacted aldehyde. 
Repeating the experiment with one equivalent of pyridine and one equivalent of p-
toluenesulfonic acid led to nearly complete formation of the hydrazone in the first ten 
minutes of the reaction and a partial recovery of final phosphonate yield. These results 
suggest that the poor reactivity of the aniline- and pyridine-containing substrates arises 
from their basicity. In altering the protonation states of the species involved in hydrazone 
formation, base shifts the equilibrium toward the aldehyde and hydrazide, resulting in a 
much smaller pool of hydrazone to react productively.12 If this is the case, Le Chatlier’s 
Principle suggests that active removal of water from the reaction should also help to drive 
the reaction forward. Several desiccant additives were screened in the reaction 3,4-
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dimethoxybenzaldehyde (8a) in the presence of one equivalent of pyridine, but they were 
all substantially less effective than one equivalent of strong acid. 
 Unfortunately, when 3-formylpyridine and 4-formylpyridine were subjected to the 
reaction conditions along with one equivalent of p-toluenesulfonic acid, very poor yields 
were obtained, perhaps because the resulting pyridinium substrate is so electron-poor. 
Further studies on these substrates were not performed due to time constraints, but these 
results suggest it might be possible to obtain good yields for substrates containing a 
pyridyl moiety, provided that an acid additive is used and that the reactive carbonyl is not 
adjacent to the ring. 
  Another substrate that gives low yields in this reaction is 4-
methoxybenzaldehyde, which decomposes with the loss of methanol (methanol observed 
by 1H NMR). This is strange, given that 3-methoxybenzaldehyde and 3,4-
dimethoxybenzaldehyde both give good yields with no sign of methanol formation. 
Control reactions show that both hydrazide and phosphite are necessary for this 
decomposition. The mechanism of this decomposition is unclear, but the satisfactory 
reaction yields with 4-fluorobenzaldehyde (Table 6.2, entry 5) suggest that an SNAr 
pathway is not at work. 
 For a number of substrates, the phosphonate yields seemed to plateau after 24-48 
hours, even though some hydrazone remained (as judged by TLC). To explore this 
observation, the reaction of 4-bromomethylbenzaldehyde (8f) was monitored by 1H and 
31P NMR (Figure 6.1). Since hydrazone formation is very rapid and quantitative (within 
NMR detection limits), hydrazone was considered to be the starting material. Indeed, the 
rate of disappearance of hydrazone slowed late in the reaction, even more than would be 
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expected by first-order behavior. This remained the case even if extra phosphite was 
added after 12 hours. Since product inhibition can cause such a phenomenon, the 
experiment was repeated with varying proportions of phosphonate pre-added to the 
reaction. The reaction rate decreased as a function of pre-added phosphonate. These 
experiments were repeated using 3,4-methoxybenzaldehyde (8a) as substrate, and the 
results were similar, as the reaction had run to completion within eight hours under the 
standard conditions, but only two-thirds of the hydrazone had been consumed in that 
period of time when one equivalent of phosphonate had been pre-added. The reason for 
this product inhibition is unclear, but sequestration of the Lewis acid catalyst by the 
phosphonate product is one possible explanation. 
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 Only poor phosphonate yields could be obtained for aliphatic aldehydes using the 
standard conditions, and most hydrazones did not crystallize readily. Pivaldhyde (10) was 
chosen as a model substrate to focus on because: the hydrazones could be crystallized; 
the NMR spectra have less splitting and are easier to interpret; and the sterically bulky 
neopentyl phosphonate 12 is difficult to access by the conventional Arbuzov reaction. 
Starting from pre-formed pivaldehyde tosylhydrazone, the tetrahedral adduct with 
dimethyl phosphite could be formed in several days at room temperature in benzene, but 
the reaction was significantly slower in other solvents. Heating the reaction actually led 
to lower conversion to the adduct, consistent with reports from Bertz and Dabbaugh 
claiming that heat drives the adduct-hydrazone equilibrium toward the hydrazone.13 Acid, 
base, and moderate heating were unable to convert it into the desired phosphonate 
product. Flash pyrolysis (250 °C) gave moderate yields of the phosphonate, but such 
conditions lacked the mildness and operational simplicity required for an attractive 
alternative to the Arbuzov reaction. (Unfortunately, this also made the GC useless as a 
tool for high-throughput screening of reaction conditions). 
 This reaction thus faced two problems: first, the adduct formation is too slow; 
second, adduct decomposition into the phosphonate is too slow. To address the first issue, 
dimethyl trimethylsilyl phosphite was tried as a more nucleophilic phosphite. Using this 
phosphite, adduct could be formed from the pivaldehyde tosylhydrazone within just 
H
N
H
O HN S
O2
NO2
NO2
P
O
OMe
OMeP(OTMS)(OMe)2
Sc(OTf)3, CHCl3
12, ~65% (NMR)10 11
Scheme 6.3. Progress towards a method for synthesizing hindered phosphonates
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several hours at room temperature. To address the second problem, it was reasoned that a 
hydrazide possessing a better arenesulfinate leaving group might be the answer. When 
pivaldehyde 2,4-dinitrobenzenesulfonylhydrazone (11) was combined with dimethyl 
trimethylsilyl phosphite in the presence of 10 mol% scandium triflate in chloroform, the 
desired dimethyl neopentyl phosphonate 12 formed in moderate yield in under a day at 
room temperature—an exciting result for such a sterically hindered substrate (Scheme 
6.3). Unfortuntately, this method could not be easily adapted to a single-step reaction 
starting from the aldehyde because the water generated in hydrazone formation readily 
decomposes the silyl phosphite. A quick screen of dessicant additives showed that a 
partial recovery of yields was possible, but a thorough examination of these conditions 
could not be done due to time constraints. 
 The first method described here works well for the direct conversion of ketones 
and with aromatic aldehydes into phosphonates. The methodology shows broad 
functional group tolerance and allows access to products that are inaccessible through the 
Arbuzov reaction. Significant progress towards adapting this method for aliphatic 
aldehydes was also achieved, and many avenues for exploration remain for developing 
such a method. For example, homogenous and heterogenous dessicants can be screened 
to remove water and enable the use of trimethylsilyl phosphites. Bulkier silyl phosphites 
(and other trisubstituted phosphites) can also be screened to see if they are less reactive 
toward water. 
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Chemistry—General 
 
All reactions were performed under ambient air using untreated solvents unless otherwise 
noted. All flasks and vials were oven-dried at 122 °C and cooled in a desiccator box 
containing anhydrous calcium sulfate. Reagents were used as purchased without further 
purification. Phenylazide reactants were prepared by coupling the corresponding boronic 
acid with sodium azide.14 Reactions were monitored by thin-layer chromatography on 
Merck Siligel 60-F254. Compounds were visualized with a UV lamp (254 nm) and stained 
with potassium permanganate solution. Column chromatography was carried out in 
accordance with the methods of Still15 using EMD-Merck silica gel 60, 230-400 mesh 
ASTM. 1H, 31P, and 13C NMR spectra were acquired on a Varian Mercury 300 MHz 
spectrometer. High-resolution mass spectrometry was performed on a JEOL JMS-600H 
HRMS using an Electrospray Ion Source. 
 
 
Chemistry—Synthesis 
 
General Procedure, aldehyde-to-phosphonate reactions. Aldehyde (0.1 mmol), 
mesitylenesulfonyl hydrazide (21.4 mg, 0.1 mmol), and yttrium triflate (5.4 mg, 0.01 
mmol) were measured into an oven-dried ½-dram vial with a disposible perylene stir-bar. 
Chloroform (1 mL) was added, and the vial was capped with a septum and stirred at room 
temperature for 10 minutes.  Typically, the solids dissolved initially, but a small amount 
of precipitate appeared after several minutes. Diethyl phosphite (26 µL, 0.2 mmol) was 
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then added, and the reaction was heated to 60 °C under stirring and monitored by TLC. 
Following the disappearance of the hydrazone (or if the rate of hydrazone disappearance 
has stalled), the reaction was filtered directly through a silica plug, eluting with 50% 
acetone in chloroform. This crude solution was then reduced in vacuo (often requiring 24 
hours on the hi-vacuum pump to remove excess diethyl phosphite) and purified by flash 
chromatography on silica to give the desired product. 
 
Diethyl 3,4-dimethoxybenzylphosphonate (9a). 8 hour reaction time. Chromatography 
using 15% acetone in dichloromethane; 25.5 mg (88.5%). 1H NMR (300 MHz, CDCl3) δ 
6.78-6.86 (m, 3H), 3.9-4.1, (m, 4H), 3.87 (s, 3H), 3.85 (s, 3H), 3.08 (d, 2H, J = 21.2 Hz), 
1.24 (t, 6H, J = 7.0 Hz); 13C NMR (126 MHz, CDCl3) δ 148.82, 148.80, 148.00, 147.97, 
123.88, 123.81, 121.93, 121.87, 112.91, 112.87, 111.19, 111.17, 62.09, 62.03, 55.85, 
55.83, 33.75, 32.64, 16.44, 16.39; 31P NMR (121 MHz, CDCl3) δ 26.70; HRMS (FAB+) 
calculated for [C13H22O5P] ([M+H]+) 289.1205, found 289.1208. 
 
Diethyl 4-azidobenzylphosphonate (9b). 36 hour reaction time. Chromatography using 
10% acetone in dichloromethane; 16.1 mg (59.9%). 1H NMR (300 MHz, CDCl3) δ 7.29 
(d, 2H, J = 8.5 Hz), 6.97 (d, 2H J = 7.8 Hz), 3.95-4.10 (m, 4H), 3.11 (d, 2H, J = 21.6 Hz) 
1.24 (t, 6H, J = 7.0 Hz); 13C NMR (126 MHz, CDCl3) δ 138.75, 131.12, 131.06, 128.38, 
128.31, 119.15, 119.13, 62.18, 62.13, 33.71, 32.60, 16.41, 16.37; 31P NMR (121 MHz, 
CDCl3) δ 25.95; HRMS (FAB+) calculated for [C11H17N3O3P] ([M+H]+) 270.1002, found 
270.1009. 
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Diethyl 3-azidobenzylphosphonate (9c). 48 hour reaction time. Chromatography using 
8% acetone in dichloromethane; 15.9 mg (59.1%). 1H NMR (300 MHz, CDCl3) δ 7.29 (t, 
1H, J = 7.7 Hz), 7.08 (d, 1H J = 7.6 Hz), 6.89-6.98 (m, 2H), 3.97-4.09 (m, 4H), 3.12 (d, 
2H, J = 21.8 Hz) 1.26 (t, 6H, J = 7.0 Hz); 13C NMR (126 MHz, CDCl3) δ 140.19, 133.76, 
133.68, 129.85, 129.82, 126.41, 126.36, 120.30, 120.25, 117.60, 117.57, 62.24, 62.18, 
34.19, 33.09, 16.41, 16.36; 31P NMR (121 MHz, CDCl3) δ 25.58; HRMS (FAB+) 
calculated for [C11H17N3O3P] ([M+H]+) 270.1002, found 270.1014. 
 
Diethyl 4-chloromethylbenzylphosphonate (9d). 24 hour reaction time. 
Chromatography using 10% acetone in dichloromethane; 19.6 mg (71.0%). 1H NMR 
(300 MHz, CDCl3) δ 7.25-7.35 (m, 4H), 4.56, (s, 2H), 3.95-4.10 (m, 4H), 3.16 (d, 2H, J = 
21.1 Hz) 1.24 (t, 6H, J = 7.0 Hz); 13C NMR (126 MHz, CDCl3) δ 136.10, 131.97, 130.12, 
130.08, 128.78, 62.21, 45.94, 34.27, 33.20, 16.40; 31P NMR (121 MHz, CDCl3) δ 25.97; 
HRMS (FAB+) calculated for [C12H19ClO3P] ([M+H]+) 277.0760, found 277.0769. 
 
Diethyl 4-fluorobenzylphosphonate (9e). 48 hour reaction time. Chromatography using 
7% acetone in dichloromethane; 16.2 mg (65.9%). 1H NMR (300 MHz, CDCl3) δ 7.22-
7.30 (m, 2H), 6.99 (t, 2H J = 8.6 Hz), 3.94-4.08 (m, 4H), 3.11 (d, 2H, J = 21.4 Hz) 1.24 
(t, 6H, J = 7.0 Hz); 13C NMR (126 MHz, CDCl3) δ 162.89, 162.86, 160.94, 160.91, 
131.27, 131.22, 131.21, 131.16, 127.38, 127.35, 127.30, 127.28, 115.50, 115.48, 115.33, 
115.31, 62.17, 62.12, 33.49, 32.38, 16.39, 16.35; 31P NMR (121 MHz, CDCl3) δ 26.09; 
19F NMR (282 MHz, CDCl3) δ -116.02; HRMS (FAB+) calculated for [C11H17FO3P] 
([M+H]+) 247.0894, found 287.0894. 
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Diethyl 4-bromomethylbenzylphosphonate (9f). 64 hour reaction time. 
Chromatography using 7% acetone in dichloromethane; 19.3 mg (60.1%). 1H NMR (300 
MHz, CDCl3) δ 7.25-7.35 (m, 4H), 4.47, (s, 2H), 3.95-4.08 (m, 4H), 3.14 (d, 2H, J = 21.7 
Hz) 1.24 (t, 6H, J = 7.1 Hz); 13C NMR (126 MHz, CDCl3) δ 136.41, 136.38, 132.08, 
132.01, 130.19, 130.13, 129.25, 129.22, 62.19, 62.14, 34.11, 33.23, 33.03, 16.40, 16.35; 
31P NMR (121 MHz, CDCl3) δ 25.93; HRMS (FAB+) calculated for [C12H19BrO3P] 
([M+H]+) 321.0250, found 321.0241. 
 
4-Chloromethylbenzaldehyde (8d). 4-Hydroxymethylbenzaldehyde16 (1.0 g, 7.3 mmol) 
was measured into a 25 mL round-bottomed flask with stirbar. Toluene (6 mL) and 
concentrated hydrochloric acid (6 mL) were added, and the mixture was rapidly stirred at 
reflux for 3 hours. The reaction was cooled and poured over ice (75 g) and extracted with 
ethyl acetate (3 x 25 mL). The organic layers were combined and washed with brine (20 
mL), dried on magnesium sulfate, and reduced in vacuo. The residue was then purified by 
flash chromatography on silica (10% ethyl acetate in hexanes) to give a volatile white 
solid. 688 mg (61%). 1H NMR (300 MHz, CDCl3) δ 10.02 (s, 1H), 7.88 (d, 2H, J = 8.3 
Hz), 7.57 (d, 2H, J = 8.0 Hz), 4.63 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 191.56, 
143.81, 136.18, 130.09, 129.09, 77.25, 77.00, 76.74, 45.23; HRMS (FAB+) calculated for 
[C8H7OCl] ([M+H]+) 154.0185, found 154.0142. 
 
4-Azidomethylbenzaldehyde. Sodium Azide (134 mg, 2.2 mmol) was measured into a 2 
dram vial with stirbar. DMSO (5 mL) was added, and the mixture was allow to stir until 
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it dissolved (3 hours). 4-Chloromethylbenzaldehyde (309 mg, 2.0 mmol) was then added 
in one portion, and the reaction was allowed to stir at room temperature for 18 hours, at 
which point it was poured over ice-water (25 mL) and extracted with diethyl ether (4 x 20 
mL). The organic layers were combined and washed with ice-water (3 x 10 mL), washed 
with brine (10 mL), dried on magnesium sulfate, and reduced in vacuo to give 
quantitative yield of a colorless oil. 1H NMR (300 MHz, CDCl3) δ 10.03 (s, 1H), 7.91 (d, 
2H, J = 8.2 Hz), 7.50 (d, 2H, J = 8.0 Hz), 4.46 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 
191.65, 142.10, 136.15, 130.22, 128.48, 77.26, 77.01, 76.75, 54.27; HRMS (FAB+) 
calculated for [C8H7N3O] ([M+H]+) 161.0589, found 161.0593. 
 
3-Chloromethylbenzaldehyde. Slightly impure 3-hydroxymethylbenzaldehyde17 (650 
mg, ~4 mmol) was measured into a 25 mL round-bottomed flask with stirbar. Toluene (6 
mL) and concentrated hydrochloric acid (6 mL) were added, and the mixture was rapidly 
stirred at reflux for 3 hours. The reaction was cooled and poured over ice (75 g) and 
extracted with ethyl acetate (3 x 25 mL). The organic layers were combined and washed 
with brine (20 mL), dried on magnesium sulfate, and reduced in vacuo. The residue was 
then purified by flash chromatography on silica (12% ethyl acetate in hexanes) to give a 
colorless liquid. 519.1 mg (~85%). 1H NMR (300 MHz, CDCl3) δ 10.03 (s, 1H), 7.91 (m, 
1H), 7.85 (dm, 1H, J = 7.6 Hz), 7.67 (dm, 1H, J = 7.6 Hz), 7.55 (t, 1H, J = 7.6 Hz), 4.65 
(s, 2H); HRMS (FAB+) calculated for [C8H7OCl] ([M+H]+) 154.0185, found 154.0153. 
 
4-Bromomethylbenzaldehyde (8f). 4-Hydroxymethylbenzaldehyde (680 mg, 5 mmol) 
was measured into a 25 mL round-bottomed flask with stirbar. Toluene (6 mL) and 
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concentrated hydrobromic acid (6 mL) were added, and the mixture was rapidly stirred at 
reflux for 3 hours. The reaction was cooled and poured over ice (75 g) and extracted with 
ethyl acetate (3 x 25 mL). The organic layers were combined and washed with brine (20 
mL), dried on magnesium sulfate, and reduced in vacuo to give a white solid. 997 mg 
(quant.). 1H NMR (300 MHz, CDCl3) δ 10.02 (s, 1H), 7.87 (d, 2H, J = 8.3 Hz), 7.56 (d, 
2H, J = 8.0 Hz), 4.52 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 191.50, 144.23, 136.11, 
130.16, 129.67, 77.27, 77.02, 76.77, 31.98; HRMS (FAB+) calculated for [C8H7OBr] 
([M+H]+) 197.9680, found 197.9632. 
 
Dimethyl (2,2-dimethyl-1-(2-tosylhydrazinyl)propyl)phosphonate (pivaldehyde 
tosylhydrazone-dimethyl phosphite adduct). Pivaldehyde tosylhydrazone (25.4 mg, 0.1 
mmol), scandium triflate (4.9 mg, 0.01 mmol), and methoxynaphthalene internal standard 
(2.8 mg, 0.02 mmol) were measured into an oven-dried ½ dram vial. Deuterated benzene 
(1 mL) was added, followed by dimethyl phosphite (18.3 µL, 0.2 mmol), and the mixture 
was shaken to dissolve and loaded into an NMR tube. 1H and 31P NMR showed no adduct 
after 8 hours, but it was visible as a minor set of peaks (1:20 relative to the hydrazone) 
after 24 hours, and it was the dominant set of peaks (7:1 relative to the hydrazone) after 1 
week. 1H NMR (300 MHz, CDCl3) δ 7.82 (d, 2H, J = 8.3 Hz), 7.32 (d, 2H, J = 8.3 Hz), 
6.94 (m, 1H), 3.80 (d, 3H, J = 8.2 Hz), 3.76 (d, 3H, J = 8.1 Hz), 3.63 (t, 1H, J = 9.7 Hz), 
2.86 (t, 1H, J = 10.5 Hz), 2.44 (s, 3H), 0.97 (s, 9H); 31P NMR (121 MHz, CDCl3) δ 31.17. 
 
Dimethyl (2,2-dimethyl-1-(2-tosylhydrazinyl)propyl)phosphonate (pivaldehyde 
tosylhydrazone-dimethyl phosphite adduct). Pivaldehyde tosylhydrazone (12.7 mg, 
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0.05 mmol) and scandium triflate (2.5 mg, 0.005 mmol) were measured into an oven-
dried ½ dram vial. Deuterated chloroform (1 mL) was added, followed by dimethyl 
trimethylsilyl phosphite (19.1 µL, 0.01 mmol), and the mixture was shaken to dissolve 
and loaded into an NMR tube. 1H and 31P NMR showed that conversion to the adduct was 
more than 50% complete after 2 hours, mostly complete after 6 hours, and it was 
complete in under 24 hours. In the absence of scandium triflate, no adduct formation 
whatsoever was visible by NMR in 24 hours. 
 
Dimethyl neopentyl phosphonate (12). Pivaldehyde 2,4-dinitrobenzenesulfonyl 
hydrazide (16.5 mg, 0.05 mmol) and scandium triflate (2.5 mg, 0.005 mmol) were 
measured into a ½ dram vial with perylene stirbar. Chloroform was added, followed by 
dimethyl trimethylsilyl phosphite (19.1 µL, 0.01 mmol), The reaction was allowed to stir 
at room temperature, and aliquots were removed periodically by syringe and examined by 
NMR. NMR after 24 hours showed ~65% yield, as determined by integration of the 
product methylene against all tert-butyl protons and all aromatic region protons. 1H NMR 
(300 MHz, CDCl3) δ 3.72 (d, 6H, J = 10.8 Hz), 1.75 (d, 2H, J = 18.7 Hz), 1.10 (d, 9H, J 
= 0.7 Hz); 31P NMR (121 MHz, CDCl3) δ 33.01. 
 
 
Chemistry—Phosphite Oxidation Protocol 
 
Dimethyl phosphite (2 drop, 0.1 mmol) was added to acetonitrile-d3 (1.5 mL) and 
deuterated water (0.2 mL). Half of this solution was loaded into an NMR tube as a 
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control, while iodine (25 mg, 0.1 mmol) was added to the other half, and the mixture was 
sonicated to dissolve completely, then loaded into another NMR tube. After 10 minutes, a 
new set of methyl peaks were visible by 1H NMR, and the conversion was complete 
within 1 hour. 1H NMR (300 MHz, CD3CN/D2O) δ CONTROL: 6.61 (d, 1H, J = 7044 
Hz), 3.73 (s, 1.3H), 3.63 (s, 3H), 3.59 (s, 3H); δ 1 HOUR: 4.71 (s, 2.3H), 3.55 (s, 3H), 
3.51 (s, 3H); 31P NMR (121 MHz, CD3CN/D2O) δ CONTROL: 11.10; δ 1 HOUR: 0.83. 
When dimethyl isopropyl phosphonate was subjected to the same conditions, no change 
was seen by NMR. 
 
 
Chemistry—Kinetic Runs 
 
4-Bromomethylbenzaldehyde (8f, 19.9 mg, 0.1 mmol), mesitylenesulfonyl hydrazide 
(21.4 mg, 0.1 mmol), yttrium triflate (5.4 mg, 0.01 mmol), and methoxynaphthalene 
internal standard (5.0 mg, 0.0316 mmol) were measured into an oven-dried ½ dram vial 
with a disposible perylene stir-bar. CDCl3 (1 mL) was added, and the vial was capped 
with a septum. In reactions where there was an additive, it was added at this time, and the 
reactions were stirred at room temperature for 15 minutes. Diethyl phosphite (26 µL, 0.2 
mmol) was then added, and the reaction was heated to 60 °C under stirring. Periodic 
aliquots were taken in the following manner: the reactions were cooled, and 100 µL 
samples were taken, diluted with CDCl3 (0.5 mL), and examined by 1H and 31P NMR. 
The reactions were immediately returned to the heat. The reactions shown are as follows: 
1) no additive 
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3) 10 mol.% diethyl 4-methylbenzylphosphonate (2.4 µL, 0.01 mmol) 
4) 50 mol % diethyl 4-methylbenzylphosphonate (12.0 µL, 0.05 mmol) 
5) 100 mol % diethyl 4-methylbenzylphosphonate (24.0 µL, 0.1 mmol). 
Yields of hydrazone were calculated based on integration of the 1H NMR peaks of its 
ortho-methyl groups (δ 2.72) relative to the methoxy group (δ 3.92) of the internal 
standard. Yields of phosphonate were calculated based on integration of the 1H NMR 
peaks of its benzylic methylene (δ 3.20/3.13) relative to the methoxy group (δ 3.92) of 
the internal standard. Residual baseline was subtracted from each integration. Data in 
Table 6.S1. These results were qualitatively supported by the 31P NMR spectra.  
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Section 3: Chapter 7 
 
 
 
Investigations into the Role of Nitrosylation of Cysteine Residues as a 
Posttranslational Protein Modification 
 
 
Abstract: Cysteine nitrosylation as a posttranslational protein modification is 
considered. The site-specific incorporation of nitrosocysteine is not possible due to the 
fast rate of nitrosyl exchange between thiols. A system to quantify the energetics of the 
proposed nitrosothiol-aromatic interaction is outlined. 
 
 The 1998 Nobel Prize in Medicine was awarded to Ferid Murad, Robert 
Furchgott, and Louis Ignarro for “their discoveries concerning nitric oxide as a signaling 
molecule in the cardiovascular system”.1 Specifically, they showed that nitric oxide is a 
naturally-produced hormone capable of traveling significant distances within the body 
and responsible for triggering dilation of the blood vessels through binding to the central 
heme in guanylyl cyclase.2 Since their initial discoveries, a number of other physiological 
roles and mechanisms for nitric oxide have been reported.3 For example, nitric oxide has 
also been shown to bind to hemoglobin, enabling it to be carried longer distances in the 
bloodstream as part of a complex feedback mechanism for regulating oxygen delivery 
throughout the body.4 It has also been shown that nitric oxide can bind proteins at 
cysteine residues in addition to at iron.5 
 Outside of the circulatory system, nitric oxide has been shown to play a role in the 
central nervous system.6 The neuronal subtype of nitric oxide synthase is calcium 
activated,7 while the nitric oxide thus produced has been shown to down-modulate the N-
methyl-D-aspartate (NMDA) receptor, thus providing a negative feedback for calcium 
influx.8 
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 Because of its suspected role in 
memory formation, the NMDA receptor 
is of particular interest (Figure 7.1).9 As 
a ‘coincidence detector’, it requires 
glycine binding, glutamate binding, and 
membrane depolarization to activate. 
Furthermore, there are a number of sites 
for posttranslational modification that 
can influence current, activation, and/or 
interactions with other proteins. The lab 
of Stuart Lipton demonstrated nitric oxide-induced down-modulation of the NMDA 
receptor that is reversible with dithiothreitol.10 They also performed an alanine scan of all 
the cysteine residues in the protein, showing that the NR2A C399A mutant is 
unresponsive to nitric oxide, suggesting that this is the key cysteine residue for 
nitrosylation. However, they lacked a method for selectively nitrosylating that residue in 
the wild-type receptor, which would provide stronger and more direct support of that 
hypothesis. 
 Given our lab’s expertise in the site-specific incorporation of unnatural amino 
acid residues,11 we hoped that we might be able to site-specifically incorporate 
nitrosocysteine into the NMDA receptor to establish the key site of nitrosylation. This 
strategy could also be useful in studying other proteins that undergo cysteine 
nitrosylation. However, this first required some controls to explore the stability of the 
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nitrosothiol group and whether it was 
sufficiently robust to survive our 
protocols for unnatural amino acid 
incorporation. 
 The literature reports that the 
energy barrier for uncatalyzed S-NO bond 
cleavage is too high (> 30 kcal/mol) to 
occur under physiological conditions.12 
However, there are other mechanisms by 
which a nitrosothiol might degrade.13 
Specifically, nitrosyl transfer from one thiol to another is known to be a rather facile 
process.14 Sterically hindered thiols are known to react more slowly, but there are 
multiple literature reports of this happening on a timescale of minutes, consistent with our 
observations. Since our unnatural amino acid incorporation protocol requires in-cell 
incubation times of 1-2 days, site-specific incorporation of nitrosocysteine using this 
method is not feasible. Likewise, no feasible ‘caged’ nitrosocysteine residues could be 
envisioned,15,16 and more chemically stable structural analogs did not seem worth 
pursuing (e.g., the sulfur-to-carbon analog C-N=O would rapidly rearrange to the oxime 
and have radically different electronic properties). 
 
 For a posttranslational modification to alter protein function, the change must 
chemically alter its sterics and/or electronics sufficiently to induce a conformation change 
or change its binding affinity for other molecules. Glycosylation and ubiquitinylation are 
NMeMe
SO2
NHHS
NMeMe
SO2
NHONS
NMeMe
SO2
HN SH
NMeMe
SO2
HN SNO
t-BuONO
Scheme 7.1. It has been reported that
fluorescence is reversibly quenched in these 
thiol-tethered dansyl derivatives (ref. 19).
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large enough to alter binding properties. Phosphorylation is a small change sterically, but 
it adds an ionic charge, which can produce a large effect. Nitric oxide binding at iron can 
displace other ligands or change the preferred coordination geometry of the metal. In 
contrast nitrosylation at sulfur is a more modest alteration. The nitrosyl group is so small 
that sterics are hardly altered, while the change from sulfhydryl involves no change in 
charge. 
 It has been proposed that cysteine nitrosylation meaningfully increases the 
residue’s affinity for aromatic amino acids.17 This mechanism has been suggested to 
operate in the NMDA receptor, hemoglobin, and fibrinogen.18 However, there is scant 
evidence supporting how this could be possible on a chemical level. Specifically, there is 
one report in which a thiol tethered to a dansyl group exhibits some fluorescence 
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quenching upon addition of a nitrosylating agent (Scheme 7.1).19 However, there is no 
rigorous quantification of this interaction, and the forces underlying it are unclear. 
 To answer these questions, we proposed a chemical double-mutant cycle 
experiment using a designed system modeled after those used by the lab of Chris Hunter 
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(Scheme 7.2).20 This design should allow a value to be assigned to 
a nitrosothiol-aromatic interaction; if it is significiant, computation 
could be done to further explore its basis. In the two contexts 
wherein interactions between specific nitrosothiols and specific 
aromatics have been reported, the aromatic residue was tyrosine. With a sample size of  
two, this could be pure coincidence, or it could suggest something unique about tyrosine 
(e.g., one could envision a hydrogen bond between the phenolic proton and the terminal 
oxygen of the nitrosothiol; Figure 7.2). For this reason, a phenol was chosen as the 
aromatic component of the mutant cycle studies. 
 Most reactions required to synthesize these molecules were well-precedented in 
the literature and proceeded without incident, but the last couple of steps gave some 
difficulty (Scheme 7.3). First, conditions that would cleanly deprotect the methyl ether of 
10 without affecting the amide linkages could not be found. Second, the amide linkages 
in 5 proved difficult to forge. Given these challenges, along with our general skepticism 
towards the ‘nitrosothiol-aromatic interaction’, we chose to abandon this project after a 
predetermined time allotment had been exceeded. 
O
R S N O H
Figure 7.2. Phenol-
nitrosothiol
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Chemistry—General 
 
All reactions were performed under argon using solvents that were dried and purified 
according to the method of Grubbs.21 All flasks and vials were oven dried at 122 °C and 
cooled in a desiccator box containing anhydrous calcium sulfate. Nitrosothiols were 
prepared using sodium nitrite according to literature procedure.22 The aryl iodide was 
synthesized according to the protocol of Ban.23 Compounds whose syntheses are not 
presented here are known compounds prepared according to the methods of Hunter.24 
Reactions were monitored by thin-layer chromatography on Merck Siligel 60-F254. 
Compounds were visualized with a UV lamp (254 nm) and stained with potassium 
permanganate solution.  Column chromatography was carried out in accordance with the 
methods of Still25 using EMD-Merck silica gel 60, 230-400 mesh ASTM. 1H and 13C 
NMR spectra were acquired on a Varian Mercury 300 MHz spectrometer. High-
resolution mass spectrometry was performed on a JEOL JMS-600H HRMS using an 
Electrospray Ion Source. 
 
 
Chemistry—Synthesis 
 
2,6-diisopropyl-4-methoxyaniline (8). 4-Iodo-2,6-Diisopropylaniline (3.03 g, 10 mmol), 
copper(I) iodide (190 mg, 1 mmol), phenanthroline (360 mg, 2 mmol), cesium carbonate 
(4.5 g, 14 mmol), and methanol (10 mL) were measured into a pressure tube with stirbar. 
The mixture was stirred on a oil bath at 110 °C for 20 h, then cooled, diluted with ethyl 
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acetate (50 mL), and filtered through a silica plug. The residue was then purified by flash 
chromatography on silica (10% ethyl acetate in hexanes) to give 1.39 g (67.1%).26 1H 
NMR (300 MHz, CDCl3) δ 6.67 (s, 2H), 3.80, (s, 3H), 3.48 (bs, 2H), 2.98 (septet, 2H, J = 
6.9 Hz), 1.29 (d, 12H, J = 6.6 Hz); 13C NMR (126 MHz, CDCl3) δ 152.98, 134.47, 
134.04, 108.86, 55.78, 28.35, 22.66; LRMS (FAB+) calculated for [C13H22NO]+ ([M+H]+) 
208.1696, found 208.1668. 
 
bis[2,6-diisopropyl-4-methoxyaniline]-isophthaloyl diamide (10). 2,6-diisopropyl-4-
methoxy aniline (1.48 g, 7.1 mmol) was added to 50 mL round-bottom flask with stirbar. 
Dichloromethane (10 mL) and triethylamine (1.04 mL, 7.5 mmol) were added by syringe, 
followed by the slow addition of isophthaloyl dichloride (3.4 mmol)27 over 1 hour by 
syringe pump at room temperature. After 16 hours the reaction was diluted with 
dichloromethane (100 mL), washed with 1N aq. HCl (2 x 50 mL), washed with 2N aq. 
NaOH (1 x 50 mL), dried on sodium sulfate, and reduced in vacuo. The residue was then 
recrystallized from 40:60 dichloromethane:petroleum ether to give 1.17 g (63.2%). 13C 
NMR (126 MHz, CDCl3) δ 166.53, 159.79, 148.11, 135.38, 130.46, 129.56, 126.26, 
123.81, 109.28, 55.47, 29.34, 23.87. 
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Section 3: Chapter 8 
 
 
 
Synthetic Efforts Towards a Fluorinated Dopamine Analog 
 
 
Abstract: α,α-difluorodopamine was envisioned as a potential agonist for probing 
the binding site of the D2 dopamine receptor. Its synthesis was attempted, but it was 
ultimately shown that the molecule is highly unlikely to be stable enough for 
pharmacological testing. 
 
 The dopamine D2 receptor is a G protein-coupled 
receptor that accepts dopamine (1) as its native ligand (Figure 
8.1).1 Studies in the Dougherty lab have implicated tryptophan 
6.48 of the D2 receptor as involved in binding the ammonium moiety of dopamine.2 This 
assignment was made through structure-function studies in which fluorinated tryptophan 
residues were incorporated at the 6.48 site. These experiments  demonstrated that the 
receptor’s sensitivity to dopamine is proportional to the cation-binding affinity of the π 
surface of the fluorinated tryptophan residue at position 6.48. This technique has been 
extensively demonstrated in various ligand-gated ion channels.3 However, Trp6.48 in the 
D2 receptor is peculiar in that the proportionality constant for this relationship is smaller 
than expected (in Coulombic terms) for a primary amine. Graphically speaking, the slope 
of the cation-π fluorination plot trendline is too shallow (Figure 8.2). 
 One possible explanation is that Trp6.48 is offset from the optimum binding 
geometry with the primary ammonium moiety of dopamine. In this case, the cation-π 
binding interaction could be better described as between Trp6.48 and the methylene 
adjacent to the ammonium moiety of dopamine (Figure 8.3).4 If that is true, increasing the 
HO
HO
NH3
1
Figure 8.1. Dopamine
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electrostatic potential of this methylene should increase the binding affinity of dopamine 
for the receptor, also causing a steeper slope in the fluorination plot of residue Trp6.48. 
We hypothesized this could be realized by synthesizing a dopamine analog that is 
fluorinated at the α-position, inductively increasing the electrostatic potential of the β-  
methylene (Scheme 8.1). Other molecules possessing this desired feature could be 
envisioned, but this molecule was the most attractive target because the steric deviation 
from dopamine is minimal, and it possesses no additional hydrogen bond donors or 
acceptors relative to dopamine. However, this molecule was unknown, and there was a 
possibility that the p-difluoromethylene phenol structure would be unstable, ejecting 
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fluoride through a quinone methide-type intermediate.5 There is some literature precedent 
for this decomposition mode, but there is also some precedent suggesting the molecule 
would be stable—namely, the stability of aqueous p-trifluoromethylphenol.6 
 The target molecule was envisioned as rising from the acidic deprotection of 
catechol acetonide 12, which itself could arise from the reduction from amide 11, which 
is a known compound 
(Scheme 8.2). In a forward 
sense, the protection of 
catechol with acetone was 
accomplished in hot toluene in 
the presence of phosphorus 
pentoxide. Submitting this 
liquid to Friedel-Crafts conditions with ethyl chlorooxalate gave ketoacid 9 as a viscous 
orange liquid. Treatment of this compound with DeoxoFluor at room temperature over 3 
days, followed by quench with aqueous ammonia yielded the difluorinated amide 11 as 
HO
HO
NH3
F F
HO
HO
NH3
HO
HO
NH3
F F
B
HO
O
NH3
F
?
1 5
5 6
Scheme 8.1. Difluoride 5 may form a stronger cation-π 
than dopamine, but decomposition is a concern.
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fine, white, needle-like crystals. This solid was then reduced with borane-dimethylsufide 
to give the primary amine 12 as a colorless liquid. 
 Methanolic HCl handily deprotected the acetonide, giving a white hydrochloride 
salt upon addition to diethyl ether. Unfortunately, NMR revealed that the geminal 
difluoride was no longer present and had instead hydrolyzed to a ketone (13). After 
screening a variety of conditions, it was discovered that low yields of the desired product 
could be isolated using chilled trifluoroacetic acid or boron trifluoride-etherate in 
dichloromethane. Interestingly, NMR of these deprotection mixtures showed that some 
amount of material was defluorinating prior to acetonide deprotection, which was 
surprising because a deprotonated phenolate intermediate was expected to be necessary to 
enable fluoride loss. 
 To explore this curiosity, a commercial sample of p-trifluoromethylphenol was 
exposed to a variety of the acidic deprotection conditions screened with acetonide 12. 
Fluoride loss was not observed in any of these cases. When amide 11 was exposed to the 
HO
HO
O
O
Me
Me
O
O
Me
Me
OEt
O
O
O
O
Me
Me
OEt
O
F F
O
O
Me
Me
NH2
O
F F
O
O
Me
Me
NH2
F F
HO
HO
NH3
O
12 13
1110
987
acetone
P2O5
ClC(O)COOEt
AlCl3
DeoxoFluor NH4OH
BH3•SMe2 various
conditions
Scheme 8.2. Synthesis of difluorinated dopamine 5 (failed).
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acidic deprotection conditions, fluoride loss was observed. These results suggested that 
the β-nitrogen was necessary for the observed fluoride loss. To test this theory, difluoride 
15 was synthesized (Scheme 8.3). When this compound was subjected to acidic acetonide 
deprotection conditions (TFA or pTSA in D2O/CD3OD, monitored by NMR), fluoride 
loss was still observed, but at a slower rate. This difference was not dramatic enough to 
invoke any major contribution from anchimeric assistance. 
 Even though small quantities of the desired compound could be synthesized, the 
stability tests showed that fluoride loss was enough of a concern that it would be 
uncertain whether a pure population of agonist is being observed in pharmacological 
tests. This project was therefore abandoned. 
O
O
Me
Me
O
O
Me
Me
Me
O
O
O
Me
Me
Me
F F
15148
AcCl
AlCl3
DeoxoFluor
Scheme 8.3. Synthesis of difluoride 15
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Chemistry—General 
 
All reactions were performed under argon using solvents that were dried and purified 
according to the method of Grubbs.7 All flasks and vials were oven dried at 122 °C and 
cooled in a desiccator box containing anhydrous calcium sulfate. Commercial reagents 
were used as purchased. (3,4-(dimethylmethylene)dioxybenzene) difluoroacetamide 11 
was prepared according to literature procedure.8 Reactions were monitored by thin-layer 
chromatography on Merck Siligel 60-F254. Compounds were visualized with a UV lamp 
(254 nm) and stained with potassium permanganate solution.  Column chromatography 
was carried out in accordance with the methods of Still9 using EMD-Merck silica gel 60, 
230-400 mesh ASTM. 1H, 31P, and 13C NMR spectra were acquired on a Varian Mercury 
300 MHz spectrometer. High-resolution mass spectrometry was performed on a JEOL 
JMS-600H HRMS using an Electrospray Ion Source.  
 
 
Chemistry—Synthesis 
 
2-(3,4-(dimethylmethylene)dioxybenzene)-2,2-difluoro ethylamine (12). Amide 11 
(1.94 g, 8 mmol) was measured into a 50 mL oven-dried round-bottomed flask with 
stirbar and condenser and purged 3x with argon. THF (20 mL) was added to dissolve the 
solid, and the clear, colorless solution was cooled on an icebath. Borane-dimethylsufide 
(1.75 mL, 18.4 mmol)10 was then added to the stirring solution by syringe, and the 
reaction was allowed to reach room temperature under stirring. Some slight bubbling was 
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observed, and the reaction was monitored by TLC (2:1 hexanes:ethyl acetate; stain with 
ninhydrin). After 20 hours, the reaction was again cooled on an icebath, and 6N HCl (5 
mL) was added dropwise with furious bubbling. This was allowed to stir a further 6 
hours, then the reaction was basified and extracted with 3 x 20 mL ethyl acetate. The 
combined organic layers were washed with 1N NaOH (20 mL), brine (20 mL), dried on 
MgSO4, and reduced in vacuo to give a yellow liquid. This residue was purified by 
chromatography on silica (40% ethyl acetate in hexanes) to give 12 as a colorless liquid 
(673 mg, 36.7%). 1H NMR (300 MHz, CDCl3) δ 6.88-6.93 (m, 1H), 6.82, (d, 1H, J = 1.5 
Hz), 6.73 (d, 1H, J = 8.1 Hz), 3.12 (t, 2H, J = 14.4 Hz), 1.67 (s, 6H), 1.38 (bs, 2H); 13C 
NMR (126 MHz, CDCl3) δ 148.99, 148.96, 147.87, 129.20, 128.84, 128.49, 125.11, 
121.90, 119.04, 118.99, 118.90, 118.81, 108.20, 106.00, 105.92, 105.83, 50.09, 49.68, 
49.26, 26.09; 19F NMR (282 MHz, CDCl3) δ -104.0; HRMS (FAB+) calculated for 
[C11H14NO2F2] ([M+H]+) 230.0993, found 230.0990. 
 
4-acetocatechol acetonide (14). Aluminum chloride (2.0 g, 15 mmol) was measured into 
an oven-dried 25 mL round-bottomed flask with stirbar and purged 3x with argon. 
Dichloromethane (2 mL) was added, and the mixture was cooled on an icebath. Acetyl 
chloride (0.7 mL, 10 mmol) was then added dropwise over 30 minutes, followed by the 
dropwise addition of catechol acetonide 8 (1.5 g, 10 mmol). The reaction was then 
allowed to warm to room temperature and stirred for 1 hour, then poured over 50 grams 
of ice. The mixture was extracted with dichloromethane, washed with saturated aqueous 
NaHCO3, dried on MgSO4, and reduced in vacuo. The residue was then purified by flash 
chromatography on silica (10% ethyl acetate in hexanes) to give 14 as a yellow oil (323 
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mg). 1H NMR (300 MHz, CDCl3) δ 7.51 (dd, 1H, J = 1.8, 8.1 Hz), 7.34, (d, 1H, J = 1.8 
Hz), 6.75 (d, 1H, J = 8.1 Hz), 2.52 (s, 3H), 1.69 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 
196.58, 151.89, 148.15, 131.81, 124.53, 119.54, 108.06, 107.86, 26.64, 26.13; HRMS 
(FAB+) calculated for [C11H12O3] ([M+H]+) 192.0786, found 192.0788. 
 
3,4-(dimethylmethylene)dioxybenzene-1,1-difluoroethane (15). Ketone 14 (295 mg, 
1.5 mmol) was measured into an oven-dried 2 dram vial with stirbar and purged 3x with 
argon. DeoxoFluor (400 µL, 2.1 mmol) was added, and the mixture was stirred at room 
temperature for 40 hours. The reaction was then heated to 75 °C for 24 hours. The 
reaction was then cooled and quenched with ice and extracted with chloroform. The 
organic layer was dried on MgSO4 and reduced in vacuo. The crude product was then 
filtered through a silica plug using 20% ethyl acetate in hexanes. The filtrate was then 
purified by flash chromatography on silica (5% ethyl acetate in hexanes) to give 15 (31.5 
mg, 9.8%).1H NMR (300 MHz, CDCl3) δ 6.94 (d, 1H, J = 7.8 Hz), 6.87, (d, 1H, J = 1.8 
Hz), 6.72 (d, 1H, J = 7.8 Hz), 1.88 (t, 3H, J = 17.7 Hz), 1.68 (s, 6H); 13C NMR (126 
MHz, CDCl3) δ 148.67, 147.75, 132.02, 131.66, 131.31, 125.16, 121.99, 118.88, 118.83, 
118.26, 118.17, 118.09, 108.00, 105.60, 105.52, 105.44, 29.93, 26.53, 26.13, 26.08, 
25.72; 19F NMR (282 MHz, CDCl3) δ -85.59 (q, J = 18.0 Hz). 
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Appendix 1 
 
 
 
The Development of a New MALDI-TOF MS Method for the Analysis 
of Amino Acid-dCA Esters 
 
 The standing group protocol for assaying amino acid-dCA esters was electrospray 
MS. However, prior to assay, the esters were purified by HPLC using an ammonium 
acetate buffered phase, and the ammonium ions interfered with obtaining a good mass 
spectrum by electrospray. Therefore, a rigorous desalting protocol was needed prior to 
MS; the protocol took at least 4 days, which slowed progress, especially in cases where 
the esterification reaction was unreliable and needed to be run multiple times. In contrast, 
MALDI MS benefits from the addition of ammonium ions, which are often the ion source 
(ammonium is typically added to the sample prior to MALDI). I therefore worked with 
Mona Shahgholi to develop a MALDI-based protocol for analyzing these compounds, 
using the solvated fractions obtained directly from the HPLC. We screened several 
different matrices, concentrations, and ratios to develop the following protocol: 
 
Note 1: the sample does NOT need to be desalted prior to MALDI; however, it should be 
desalted thereafter (removal of ammonium ions) by three cycles of 
dissolution/lyophilization using a 25 mM acetic acid solution. If ammonium ions remain, 
they could inhibit the subsequent enzymatic tRNA ligation.  
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Note 2: the reflector mode used in this protocol should allow for < 0.1% mass error.  I 
have never seen it to give greater than 0.02% mass error.  The error increases (along-the-
baseline resolution gets worse) for more concentrated samples. 
 
Preparation of Matrix Solutions: 
1) 10 mg/mL 6-aza-2-thiothymine (ATT) in 1:1 water:acetonitrile 
2) 10 mg/mL ammonium citrate (dianion) in 1:1 water:acetonitrile 
3) 9:1 mixture of solutions 1:2 above 
4) 50 µM dCA-AA in water  
a) for a ligation efficiency of 5-20 % (HPLC integration), the product 
fraction collected directly off the HPLC should work ‘as is’, without dilution (for 
higher ligation efficiencies, for starting materials, or for reactions run with more 
than 10 mg dCA, the collected fractions should be diluted accordingly) 
b) as low as 5 µM should still give good spectra; for solutions above 50 µM, 
significant gas-phase dimerization can be observed, and the resolution along the 
baseline decreases 
5) 9:1 mixture of solutions 3:4 above 
 
Spot 0.3 µL of solution 5 above onto the MALDI sample plates and allow to dry. (Note 
that this spot represents only 1.5 pmol = 1 ng dCA-AA, and we have shown that less that 
0.1 ng still works—the sensitivity of the MALDI is very good.) 
 
The method used is: 
• Jeff Bics  Reflector 1500 
• Two parameters may need to be adjusted: 
− Mass Range (500-1500 amu) 
− Laser Intensity (start around 2200, but if that fails to produce a good 
spectrum, adjust it up—I have needed to go as high as 3200 before) 
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Appendix 2 
 
 
 
Investigations into an Organocatalytic LUMO–SOMO Cascade 
 
 
 During my brief time in the MacMillan lab, my project was to explore the 
feasibility to a LUMO–SOMO (Friedel-Crafts–radical cyclization) organocatalysis 
cascade (Scheme A2.1). The conclusion is that such a sequence is quite doubtful: the 
oxidizing conditions needed for the SOMO reaction also oxidize the aniline substrate. 
Even if milder SOMO conditions could be developed, the oxidation potentials of 
enamines and anilines suggest that the electron-rich aniline would always be oxidized 
under conditions that are sufficient to oxidize the catalytic enamine intermediate. 
Furthermore, the aniline concentration in the reaction will always vastly exceed the 
enamine concentration, which will always be present only in catalytic amounts. 
 The best hope for this sort of cascade lies not in aniline substrates, but in less 
readily-oxidized aromatic heterocycles—such as furans—which can participate in the 
first step as activated potassium trifluoroborate salts,1 then become significantly less 
readily-oxidized following the Friedel-Crafts (LUMO) step. In this case, the aromatic 
component is more likely to withstand the SOMO conditions. 
NMe
Me
Me O
NMe
Me
O
Me
NMe
Me
O
Me
X
2° amine 2° amine
oxidant
Scheme A2.1. Proposed one-pot organocatalytic cascade.
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